WO1986007060A1 - Cloning and expression of host-protective immunogens of ibdv - Google Patents
Cloning and expression of host-protective immunogens of ibdv Download PDFInfo
- Publication number
- WO1986007060A1 WO1986007060A1 PCT/AU1986/000156 AU8600156W WO8607060A1 WO 1986007060 A1 WO1986007060 A1 WO 1986007060A1 AU 8600156 W AU8600156 W AU 8600156W WO 8607060 A1 WO8607060 A1 WO 8607060A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ibdv
- polypeptide
- protein
- structural protein
- antigenicity
- Prior art date
Links
- 238000010367 cloning Methods 0.000 title claims description 15
- 241000702626 Infectious bursal disease virus Species 0.000 claims abstract description 141
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 122
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 106
- 229920001184 polypeptide Polymers 0.000 claims abstract description 100
- 101710172711 Structural protein Proteins 0.000 claims abstract description 53
- 239000002773 nucleotide Substances 0.000 claims abstract description 40
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 40
- 108020004414 DNA Proteins 0.000 claims abstract description 27
- 102000053602 DNA Human genes 0.000 claims abstract description 20
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 191
- 102000004169 proteins and genes Human genes 0.000 claims description 169
- 241000700605 Viruses Species 0.000 claims description 59
- 108020001507 fusion proteins Proteins 0.000 claims description 52
- 102000037865 fusion proteins Human genes 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 28
- 239000002243 precursor Substances 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 4
- 238000006386 neutralization reaction Methods 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims 3
- 244000144977 poultry Species 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 72
- 239000002299 complementary DNA Substances 0.000 description 46
- 241000287828 Gallus gallus Species 0.000 description 35
- 235000013330 chicken meat Nutrition 0.000 description 35
- 239000000427 antigen Substances 0.000 description 33
- 108091007433 antigens Proteins 0.000 description 33
- 102000036639 antigens Human genes 0.000 description 33
- 239000012634 fragment Substances 0.000 description 29
- 230000003472 neutralizing effect Effects 0.000 description 24
- 241000588724 Escherichia coli Species 0.000 description 22
- 239000000499 gel Substances 0.000 description 20
- 238000001262 western blot Methods 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- 230000014616 translation Effects 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 108010005774 beta-Galactosidase Proteins 0.000 description 14
- 238000013519 translation Methods 0.000 description 14
- 102000005936 beta-Galactosidase Human genes 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000012163 sequencing technique Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 102100034343 Integrase Human genes 0.000 description 11
- 239000000020 Nitrocellulose Substances 0.000 description 11
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 229920001220 nitrocellulos Polymers 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 108010067390 Viral Proteins Proteins 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 229920001519 homopolymer Polymers 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 5
- 102000016943 Muramidase Human genes 0.000 description 5
- 108010014251 Muramidase Proteins 0.000 description 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 239000004325 lysozyme Substances 0.000 description 5
- 235000010335 lysozyme Nutrition 0.000 description 5
- 229960000274 lysozyme Drugs 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 210000001995 reticulocyte Anatomy 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 108091092328 cellular RNA Proteins 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000702673 Bovine rotavirus Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108050009160 DNA polymerase 1 Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108010059712 Pronase Proteins 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 230000010530 Virus Neutralization Effects 0.000 description 3
- 238000000376 autoradiography Methods 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241001260012 Bursa Species 0.000 description 2
- 244000135860 Capparis spinosa subsp spinosa Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000702321 Microvirus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108700010756 Viral Polyproteins Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004671 cell-free system Anatomy 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000710921 Infectious pancreatic necrosis virus Species 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241001672648 Vieira Species 0.000 description 1
- 241001265414 Vieraea Species 0.000 description 1
- ZKHQWZAMYRWXGA-MVKANHKCSA-N [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxy(32P)phosphoryl] phosphono hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO[32P](O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-MVKANHKCSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- CCAFPWNGIUBUSD-UHFFFAOYSA-N diethyl sulfoxide Chemical compound CCS(=O)CC CCAFPWNGIUBUSD-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 229940094991 herring sperm dna Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 150000002605 large molecules Chemical group 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- -1 p-aminophenyl- Chemical group 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000012205 qualitative assay Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- This invention relates to the cloning and characterisation of the infectious bursal disease virus (IBDV) genome, to the identification of cloned genes for host-protective antigens of IBDV, to the expression of cDNA inserts encoding the whole or part of host-protective antigens of IBDV in E.coli or other host cells, and to the use of the expressed antigens in the production of virus neutralizing antibodies in chickens.
- the invention further relates to the production of an effective sub-unit vaccine against IBDV utilising the expressed antigens, as well as to the use of the expressed antigens in diagnostic tests, assays and the like.
- this invention relates to a method for the use of recombinant DNA techniques in the production of "correctly" processed antigens of IBDV.
- the production of such "correctly” processed antigens is of particular importance in ensuring, for example, that these antigens may be effectively used as vaccine components for the production of neutralising and protective antibodies.
- the polypeptides of an Australian strain (002-73) of IBDV have recently been characterised.
- prior International Patent Specification No. PCT/AU84/00256 it is disclosed that the 32Kd structural protein is a major immunogen of IBDV, and produces antibodies in chickens that neutralize the virus in vitro and protect the chickens from IBDV infection.
- a monoclonal antibody that neutralises the infectivityof IBDV, recognises an epitope encoded within the. gene for the 52Kd precursor protein; a protein processed into the 41Kd and 37Kd structural proteins of IBDV.
- a recombinant DNA molecule comprising a nucleotide sequence substantially corresponding to all or a portion of IBDV RNA, particularly the IBDV RNA segment of approximately 3400 b.p.
- the nucleotide sequence codes for all or part of at least one structural protein of IBDV.
- the DNA molecule is capable of being expressed as a polypeptide displaying antigenicity substantially corresponding to the 32Kd or 41/37 d structural protein of IBDV.
- the nucleotide sequence may be character ⁇ ised by at least a portion thereof having the base sequence substantially as shown in Figure 10 hereinafter or one or more portions of said base seq ⁇ ence.
- a recombinant DNA molecule comprising a nucleotide sequence coding for all or part of the 32Kd structural protein or the 52Kd precursor protein of IBDV, together with further portion(s) of the 3400 b.p. segment coding for further polypeptides or proteins to correctly process said 32Kd or 41/37Kd structural protein. Expression of this molecule leads to the expression of the 32Kd or 41/37 Kd structural protein as a correctly processed protein.
- Such a molecule may encode both the 32Kd structural protein as well as additional polypeptides or proteins, including proteases, required ; to correctly process the 32Kd structural protein.
- nucleotide sequence of this aspect of the invention may be obtained from natural, synthetic or semi-synthetic sources, or by manipulation of the natural material; furthermore, this
- 10 nucleotide sequence may be a naturally-occurring sequence, or it may be related by mutation, including single or multiple base substitutions, deletions, insertions and inversions, to such a naturally-occurring sequence, provided always that the DNA molecule comprising such a sequence is capable of being expressed as a polypeptide displaying the antigenicity of one or more structural proteins of IBDV.
- the nucleotide sequence may have expression
- control sequences positioned adjacent to it such control sequences being derived either from IBDV nucleic acid or from a heterologous source.
- This invention also provides a recombinant DNA 2 molecule comprising an expression control sequence having promoter sequences and initiator sequences, and a nucleotide sequence coding for all or part of at least one structural protein of IBDV.
- the invention provides a recombinant DNA cloning vehicle capable of expressing all or part of at least one structural protein of IBDV, comprising an expression control sequence having promotor sequences and initiator sequences, and a nucleotide sequence coding for all or part of at least one structural protein of IBDV.
- a host cell containing a recombinant DNA cloning vehicle and/or a recombinant DNA molecule as described above.
- polypeptides displaying IBDV antigenicity which can be produced by a host cell transformed or infected with a recombinant DNA cloning vehicle as described above.
- Such expressed polypeptides may comprise all or part of at least one structural protein of IBDV as derived from the base sequence substantially as shown in Figure 10 or one or more portion(s) of the said sequence.
- Such polypeptides can be isolated from the host cell, and if necessary purified to provide the polypeptide substantially free of host cell or other proteins. Where the expressed polypeptides are in the form of a fused polypeptide, they may be cleaved to remove the "foreign" peptide portion.
- the present invention also extends to synthetic peptides or polypeptides displaying the antigenicity of all or a portion of at least one structural protein of IBDV, particularly the 32Kd and/or 41/37Kd structural proteins.
- synthetic means that the peptides or polypeptides have been produced by chemical and/or biological means, such as by means of chemical synthesis or by recombinant DNA techniques leading to biological synthesis.
- polypeptides can, of course, be obtained by direct expression by a host-cell of a correctly processed and folded protein, or by cleavage of a fused polypeptide produced by a host cell and separation of the desired polypeptide from additional polypeptide coded for by the DNA of the host cell or cloning vehicle by methods well known in the art.
- the polypeptide may be produced synthetically, for example by the well-known Merrifield solid-phase synthesis procedure [Marglin and Merrifield, (1970)] .
- polypeptides displaying antigenicity characteristic of structural proteins of IBDV will have utility in serological diagnosis, and in the preparation of single or multivalent vaccines against IBDV by methods well known in the art of vaccine manufacture. Further details of such vaccines, and of methods of use thereof, as well as of quantitative and qualitative assays, are disclosed in International Patent Specification No. PCT/AU84/00256.
- Figure 1 shows electrophoresis of IBDV RNA translation products synthesised in rabbit reticulocyte lysate, particularly the MW of translation products and coding assignments of IBDV RNA segments (i) MW standards; (ii) unfractionated IBDV RNA; (iii) large segment of IBDV RNA; (iv) small segment of IBDV RNA.
- Figure 2 is a map of cloned inserts covering the entire large RNA segment of IBDV.
- DNA poly erase 1, SI nuclease, DNase 1, and RNase A Boehringer
- rabbit reticulocyte lysate [ ⁇ - 32P]ATP, [ ⁇ - 32P] ATP, [35S]methionine, and PstI (Amerisham) ;
- IBDV strain 002-73 was first reported by Firth (1974) in commercial chicken flocks in Australia and confirmed as IBDV at the Central Veterinary Laboratory, Weybridge, U.K. The virus was routinely passaged in 4- to 6-week old SPF White Leghorn chickens, isolated from bursas 3 days after infection, and purified by successive fractionations on sucrose and CsCl gradients.
- Isolation and purification of IBDV RNA Homogenates of fresh infected bursas ,were spun at 17,000 g for 15 minutes at 0°. The clear supernatant was layered on top of 2-ml sucrose cushions (40%) and the virus particles were pelleted through the cushions in a Beckman SW40 rotor at 22,000 rpm at 2° for 2.5 hours. The pellets were suspended in 10 mM Tris.
- RNA in the aqueous phase recovered by precipitation with ethanol.
- the ds viral RNA was purified from the chicken cellular RNA by differential salt precipitation (Diaz-Ruiz and Kaper, 1978) .
- RNA or DNA segments were isolated from agarose gels by electrophoresis onto NA45 membrane filters followed by elution in 1M NaCl and 0.05 M arginine at 70°.
- RNA bands were excised from low melting point agarose slab gel and melted ' (70°) in 5 mol. of low salt buffer containing 0.5% SDS. The solution was extracted with phenol and the RNA in the aqueous phase precipitated with ethanol.
- Hybridization probes IBDV RNA was labeled with [ ⁇ - 32 P] following mild alkaline digestion (Goldbach et al. 1978) .
- cDNA probes were prepared from denatured ds RNA using random primers to initiate cDNA synthesis in the presence of RTase. The RNA template was then destroyed by digestion with NaOH. Nick translation of cloned DNA fragments was carried out essentially as described by Rigby et al. (1977) . All radioactively labeled probes were purified from unreacted isotopes by precipitation (3x) from 2 M ammonium acetate and isopropanol at room temperature.
- IBDV RNA (1-2 ⁇ g) in 3 ⁇ l of 10 mM phosphate, pH 6.8 was heated at 100° for 2 minutes and snap chilled in dry ice/ethanol. Methylmercurie hydroxide (1 ⁇ l of 40 mM) was then added and the mixture left at room temperature for 10 minutes. 8-Mercaptoethanol (1 ⁇ l of 700 mM) and 1 ⁇ l of RNasin (25 units) were added and the solution was incubated for a further 5 minutes at room temperature. Aliquots (1 ⁇ l) were transferred to tubes containing 5 ⁇ Ci of [ 35S.methionine (dried down) and 30 ⁇ l of rabbit reticulocyte lysate and the solution was incubated at 30° for 1 hour. The reaction mixture was • reacted in succession with chicken antiserum, rabbit anti-chicken IgG, and protein A-Sepharose (Pharmacia) .
- the protein A-Sepharose-antigen-antibody complex was washed extensively with phosphate-buffered saline containing 0.1% NP-40 and then boiled in buffer containing 2% SDS.
- the protein A-Sepharose was spun down and the translated proteins in the supernate were analysed by polyacrylamide gel electrophoresis (12.5% gel) .
- the gel was then treated with AMPLIFY (Amersham) , dried and exposed to Fuji RX film with intensifying screen (Dupont Cronex Lightening Plus AA) .
- IBDV RNA (5 ⁇ g) in 9 ⁇ ; pf 5mM phosphate buffer, pH 6.8, was heated at 100° for 2 minutes and then snap frozen. After the RNA had thawed 1 ⁇ l of 100 mM methylmercuric hydroxide was added and the mixture left at room temperature for 10 minutes. Two microliters of RNasin (50 units) and 4 ⁇ l of 700 mM ⁇ -mercaptoethanol were then added and the mixture was left at room temperature for a further 5 minutes. Ten microliters of random primers (50 ⁇ g) , which had been separately denatured by boiling and snap chilling, was then added to the mixture to prime cDNA synthesis.
- the mixture (100 ⁇ l final volume) contained RTase (50 units) and other reactants required for cDNA synthesis. Following incubation at 42° for 2 hours the RNA template was destroyed by digestion with NaOH, and the cDNA purified by gel filtration. Complementary cDNA fragments were annealed in 0.3 M NaCl at 65° for 2 hours following initial heating at 90° for 3 minutes. The solution was then allowed to cool gradually to room temperature over 1 hour. The annealed cDNA segments were repaired and chains extended with DNA polymerase 1. The ds cDNA chains were further extended with RTase, treated with DNA ligase and SI nuclease, and finally purified by gel filtration.
- the ds cDNA was C tailed with terminal transferase, annealed to G-tailed Pst-cut pBR322 (New England
- Plasmid DNA was isolated essentially by the Ish-Horowicz and Burke (1981) modification of the method described by Birnboim and Doly (1979) with the following further modifications. RNase digestion was carried out concommitantly with lysozyme treatment, and the plasmid DNA was purified from RNA breakdown products by precipitation from polyethylene glycol (6.5% PEG, 0.8 M NaCl, 0°, 1 hour) .
- the recombinant colonies were hybridized with radioactive probes as described by Grunstein and Hogness (1975) .
- the solution used for prehybridization and hybridization contained 5X Denhardt's solution, 10 mM
- HEPES HEPES (pH 7.0), 0.1% SDS, 3X SSC, 10 ⁇ g/ml E. coli tRNA, and 18 ⁇ g /ml sonicated and denatured herring sperm DNA.
- the filters were prehybridized at 65° for 2 hours, and then hybridized with radioactive probes for 16-20 hours at 65°.
- the filters were washed 4 X 30 minutes with 0.5 X SSC,0.1% SDS at 65°, and then autoradiographed using Fuji RX film and intensifying screen.
- RNA isolation procedure described above is simple and rapid, and results in a high yield of good quality RNA.
- a low-speed spin of the bursal homogenate followed by sedimentation of the virus particles through a 40% sucrose cushion resulted in the removal of virtually all the cellular DNA and over 90% of the cellular RNA.
- the total RNA was fractionated by differential salt precipitation (Diaz-Ruiz and Kaper, 1978) .
- the cellular ss RNA was precipitated from 2 M LiCl and the viral ds RNA in the supernatant could be further purified from low MW contaminants and any contaminating DNA by precipitation from 4M LiCl.
- IBDV strain 002-73 consists of two segments of ds RNA as has been shown to be the case for strain Cu-1 (Muller et al, 1979) and a strain isolated at the Central Veterinary Laboratories, Weybridge, U.K. (Todd and McNulty, 1979) .
- the two segments of IBDV RNA When electrophoresed under nondenaturing conditions the two segments of IBDV RNA appear to be 3825 and 3400 bp, respectively, when compared with DNA standards. These values correspond to MW of 2.52 x 10 and 2.2 x 10 , respectively, for the two segments.
- the two segments of IBDV ds RNA When compared under nondenaturing conditions with ds RNA segments of UK bovine rotavirus, the sizes of which were obtained by electron microscopy (Rixon et al, 1984) , the two segments of IBDV ds RNA appear to be about 3400 bp (MW 2.06 x 10 6 ) and 2900 bp (MW 1.76 x 10 6 ) , respectively.
- RNA codes for six polypeptides of Ca. MW 90Kd, 52Kd, 4lKd, 32Kd, 18Kd, and 16Kd (Fig. 1 (ii) .
- the smaller RNA segment which we have not been able to completely purify by gel electrophoresis, is translated in vitro traces of all the translation products are seen but the 90-Kd protein is consistently the most prominent one (Fig. 1 (iv) .
- DNA polymerase 1 was used to repair and extend the cDNA chains, which were then extended further with RTase.
- the ds cDNA molecules were then treated with DNA ligase followed by SI nuclease.
- the ds cDNA molecules were C tailed and annealed to G-tailed pBR322, and used to transform E.coli RRl cells.
- Recombinant colonies were hybridized with radioactive probes made from the large or small segment of IBDV RNA, and 200 colonies positive to each of the probes were randomly selected for further characterization.
- the positive colonies were screened for plasmid size by electrophoresing colony lysates on agarose mini-gels. A few of these colonies, positive to the large segment probes, were grown up in 5 ml L broth for plasmid DNA isolation.
- the plasmids were digested with PstI and the sizes of the inserts determined by electrophoresis. These inserts of defined size were "nick translated" and used separately to probe identical sets of positive colonies.
- Figure 3 shows some E.coli colonies expressing proteins positive to a monoclonal antibody (Mab 17-80) that reacts with denatured 32Kd protein of IBDV.
- Figure 4 shows proteins from E.coli colonies subjected to electrophoresis and (a) stained with Coomassie Blue, or (b) Western blotted and reacted with MAb 17-80.
- Arrows 1 and 2 indicate the positions of fusion protein and ⁇ -galactosidase, respectively.
- Samples are (i) HB 101 cells, (ii) HB 101 with pUR 290, (iii) - (viii) some recombinant clones that were identified as possible positives by reaction with MAb 17-80 (Fig.3).
- Figure 5 shows (a) the position of the insert from clone D6 on the large segment of IBDV genome; (b) the restriction map of the inserts from clones D6 and Dl.
- Figure 6 shows the determination of optimum conditions for expression of fusion proteins.
- Cells were grown to an O . ⁇ . c oo / . n U of 0.2, (i) then grown further with or without induction with 1.5mM IPTG, (ii) 1.5hr, (iii) 1.5hr + IPTG, (iv) 3.0hr, (v) 3.0hr + IPTG, (vi)
- Figure 7 shows affinity purification of fusion protein from clone Dl.
- Figure 8 shows affinity purified proteins from clones Dl and D6, subjected to electrophoresis and stained with Coomassie blue (a) , reacted with anti-0- galactosidase (b) , and reacted with anti-32Kd-monoclonal antibody (c) .
- Figure 9 shows Western blot analysis of sera from unprimed (1°) or primed (2°) chickens injected with fusion proteins from clones Dl or D6 in Freund's adjuvant. Sera obtained prior to vaccination (0) , 3 weeks after injection of fusion proteins (3) , or 4 weeks after a second injection of fusion proteins (7) .
- the materials and their sources are: DNase 1, lysozyme, agarose, BSA, isopropyl ⁇ -D-thiogalactoside (1 PTG) and l-ethyl-3(3-dimethylaminopropyl) carbodiimide (Sigma) : goat anti-mouse IgG horse radish peroxidase conjugate (GAM HRP) , goat anti-rabbit IgG horse radish peroxidate conjugate (GAR HRP) , and HRP colour in -t oe developing reagent (BioRad) : ⁇ [ Pi dATP, [ I] Protein A and Pst 1 (amersham) ; nitrocellulose filters and MA45 membrane filters (Schleicher and Schuell) ; CH-Sepharose 4B (Pharmacia) : DNA polymerase (Boehringer) ; rabbit anti-mouse IgG (Dako immunoglobulins (Denmark) . Monoclonal antibodies against
- IBDV strain 002-73 was grown and isolated as described earlier.
- Recombinant colonies were grown (37°) on nitrocellulose filters on LB plates containing 30 ⁇ g/ml ampicillin. All subsequent steps were carried out at room temperature.
- the nitrocellulose filters were placed in a chloroform atmosphere on Whatman No. 3 paper saturated with 1% SDS for 30 minutes to 1 hour.
- the filters were rinsed with 50 mM Tris-HCl (pH 7.5), 150 mM NaCl (TBS) to remove cell debris, and then incubated for 1 hour with shaking in TBS containing 3% BSA, 5mM MgCl-, l ⁇ g/ml Dnase and 40 ⁇ g/ml lysozyme. This was followed by incubation for 1 hour in supernatant from monoclonal antibodies.
- E.coli cultures (0.8 ml in Eppendorf tubes) were grown in L broth containing ampicillin for 1 - 2 hours, induced with IPTG if required, and the cells collected by centrifugation.
- the cell pellet was suspended directly in the loading buffer containing 60mM Tris-Hcl (pH 7.5), 2% SDS, 10% glycerol, 5% ⁇ -mercaptoethanol, 0.001% bromophenol blue, and boiled for two minutes. 50 ⁇ l aliquots were loaded in duplicate on two gels. Proteins on one gel were stained with Coomassie blue, and proteins on the duplicate gel transferred to nitrocellulose filter. For quick immunoassays of the isolated protein, the cell pellets were suspended in 300 ⁇ l TBS buffer containing 40 ⁇ gml lysozyme (0°, 15 minutes) and then SDS was added to 1% and the solution left at room temperature for 30 minutes.
- TBS buffer containing 40 ⁇ gml lysozyme (0°, 15 minutes)
- the cell pellet was suspended in 300 ⁇ l TBS buffer and sonicated. In either case, cell debris were removed by centifigation, and lOO ⁇ l of the supernatant blotted onto nitrocellulose filter using Schleider and Schuell Manifold apparatus. The filter was then immunoassayed as described earlier for recombinant colonies.
- Proteins electrophoresed on acrylamide gels were transferred to NC filters with Bio-Rad Transblot apparatus using buffers and protocol described by Bio-Rad. Proteins of interest were detected by immunoassaying the filter as described earlier.
- the fusion protein was purified by affinity chromatography (Ullmann, 1984) .
- Dl and D6 were emulsified in an equal volume of Freund's complete adjuvant and 1 ml injected intramuscularly into a series of adult White Leghorn chickens.
- the vaccines were injected into both specific pathogen free (SPF) chickens and chickens that had previously (> 8 weeks) been sensitized by inoculation with live IBDV.
- the chickens were revaccinated three weeks later with the respective fusion proteins emulsified in Freund's incomplete adjuvant and bled at weekly intervals throughout.
- the large segment of IBDV RNA encodes three major structural proteins including the 32Kd host-protective antigen.
- cDNA inserts hybridizable to the large segment of IBDV RNA were recovered from the cDNA library by digestion of the "mixed" plasmids with Pst 1, and the "mixed" inserts were subcloned into the Pst 1 site of pUR expression vectors 290, 291 and 292, (Ruther and Muller-Hill, 1983) and these were used to transform E.coli HB101 cells. These three vectors together contain restriction sites in all three frames at the 3' end of the lacZ gene. Insertion of cDNA in the proper cloning site leads to a fusion protein of active ⁇ -galactosidase and the peptide encoded by the forein cDNA.
- the expressed proteins were characterized by polyacrylamide gel electrophoresis and Western blotting.
- the cells grown in Eppondorf tubes in L broth were spun down and boiled in 2% SDS for 2 minutes and loaded in duplicate on two separate gels. After electrophoresis one gel was stained with Coomassie blue, and proteins from the other gel were electroblotted onto nitrocellulose filter and probed with monoclonal antibody specific for the 32 Kd polypeptide.
- the cDNA inserts obtained by digestion with Pst 1, from all the positive clones were of identical size of about 450 b.p. These inserts were "nick-translated" and hybridized with a series of cDNA clones that contain a network of overlapping fragments covering the entire large segment of the IBDV genome.
- the inserts from the expressing clones in every case, hybridized specifically with clone D6 which spans the 3' end of the large segment of IBDV RNA (see Fig. 5a) and other cDNA clones containing inserts of varying sizes from the same region of the IBDV genome.
- the inserts from the expressing clones had identical restriction maps and were of identical size. Therefore one clone, Dl, that grew well and expressed the fusion protein to a high level, was selected for further studies.
- the insert of Dl is present in the vector pUR 290. Comparison of the restriction maps
- Optimum conditions for expression 15 The optimum conditions for the expression of the fused proteins were as follows (Fig. 6) . Cells were grown in L Broth in presence of ampicillin (30 ⁇ g/ml) to an O.D. 660 of 0.2 and then induced with 1.5 mM IPTG for 4 hours. There was no significant synthesis of the
- fusion proteins from clones Dl and D6 were affinity purified as described by Ullmann (1984) .
- Ullmann (1984) When pUR vectors are used for expression the ⁇ -galactosidase
- the fusion protein is enzymatically active and will bind to a substrate for ⁇ -galactosidase (Ullmann).
- the highly purified fusion proteins (Dl and D6) and free ⁇ -galactosidase (Fig. 8a) were recovered at a fairly high concentration of ca. 1 - 2 mg/ml, and yielded up to 20 g of affinity purified protein per litre of culture.
- the fusion protein was subject to proteolytic degradation as evidenced by the presence of substantial amounts of polypeptides having electrophoretic mobilities similar to or faster than ⁇ -galactosidase.
- Three bands are seen in affinity purified proteins from clones D6 and Dl. All of the bands react with anti- ⁇ -galactosidase IgG (Fig. 8b) , while only bands la and lb, from D6 and Dl respectively, react with the anti-32 Kd ⁇ monoclonal (Fig. 8c) .
- Mabs monoclonal antibodies that recognise the 32 Kd structural protein of IBDV and/or neutralize the virus. These fall into two classes. One class of Mabs (e.g.17-80) reacts with the 32 Kd proteins on Western blots but do not neutralize the virus, while the other class of Mabs (e.g.17-82) neutralize the virus but do not significantly react with the 32 Kd protein on Western blots. This suggests that the virus neutralizing monoclonal antibodies recognize a conformational epitope.
- the fusion proteins expressed in clones Dl and D6 when boiled in SDS react very strongly with monoclonal antibodies that recognize the 32 Kd structural proteins on Western blots. Both the expressed fusion proteins, when not treated with SDS, also react weakly but specifically with monoclonal antibodies that neutralize the virus. What is significant is that the IBDV polypeptide expressed in clone Dl is only 150 amino acid residues long and constitutes about half of the 32 Kd protein but contains the epitope that is recognized by the MAb that is specific for the 32 Kd protein on Western Blots (17-80) , and at least a part of the epitope recognised by the MAb that neutralizes the virus (17-82) .
- Fusion proteins from clones Dl and D6 were injected into both SPF chickens and chickens previously sensitised with live IBDV as described under Materials and Methods. The specificity of the antibodies in the sera obtained from both groups of chickens was analysed by Western blotting of whole IBDV particles boiled in SDS prior to electrophoresis (Fig.9). Previously sensitized chickens had antibodies to the 32 Kd, 37 Kd and 42 Kd structural polypeptides of IBDV at relatively low levels prior to vaccination with the fusion proteins. Fusion proteins from clones D6 and Dl recalled a specific anti-32 Kd antibody response in all these chickens, while the intensity of binding to the other structural proteins remained unchanged.
- the fusion proteins In unprimed SPF chickens the fusion proteins induced the synthesis of antibodies in only some of the chickens. When antibodies were detected, however, they were specific by Western blotting for the 32 Kd structural polypeptide of IBDV. Thus the fusion proteins expressed in clones D6 and Dl induce antibodies specific for the 32 Kd polypeptide in both primed and unprimed chickens.
- the sera obtained from the sensitized and SPF chickens vaccinated with the fusion proteins were assessed by the ELISA and micro-virus neutralization assays which were designed to recognize the protective immunogen in its native conformation.
- the levels of antibody detectable by ELISA did not increase by more than 2-4 fold above pre-existing levels in sensitized chickens or above base-line levels ( ⁇ 1:100) in SPF chickens, even though they reacted very strongly with Western blotted viral proteins.
- the virus neutralization assay also showed no dramatic increase in the levels of antibody in previously sensitized chickens, but detected a titre of 1:320 to 1:160 in one of two SPF chickens vaccinated with affinity purified protein from clone Dl.
- the antibody titre peaked 3 to 4 weeks after the second injection of protein from clone Dl and persisted for more than 6 weeks.
- Western blotting the polyclonal response of this chicken to Dl protein was specific for the 32 Kd polypeptide of IBDV.
- the IBDV protein could have been proteolytically cleaved off the ⁇ -galactosidase and assumed the conformation required for inducing virus neutralizing antibody response.
- unfused 32Kd protein has been produced by expressing the gene for the 32Kd protein in vectors that produce unfused proteins. This unfused protein reacted with the virus neutralizing MAb 17-82, though to a lesser extent than with MAb 17-80 that preferentially reacts with denatured 32Kd protein.
- one avenue for producing the 32Kd antigen with the correct three-dimensional structure is to cleave off the IBDV antigen from affinity purified fusion protein by chemical or enzymatic cleavage at the junction of the two proteins. Although this method may require a further refolding step, the level of expression of fusion protein, in comparison to unfused protein, is very high and the fusion protein can be readily purified by affinity chromatograph .
- Figure 10 shows sequence analysis of the large RNA segment of IBDV.
- the predicted amino acid sequence is presented in single letter code above the nucleotide sequence derived from cDNA clones. There are no other extensive open reading frames. The amino acid sequences are numbered sequentially from the N-terminus of the 37Kd protein as position 1. The region encompassed by cDNA clones M7, G6, L6, D6 and Dl are indicated. Dibasic residues are boxed and the repeat unit A-X-A-A-S is similarly highlighted. N-terminal sequences derived from tryptic peptides are shown overlined as (- - - ->) for the 37Kd, (....>) for 28Kd and ( >) for the 32Kd protein. Only the N-terminus of the 37Kd protein could be obtained by direct sequencing on intact proteins and this is shown from residue 1. Results and Discussion Random nucleotide sequencing
- Single-stranded templates were sequenced by the primed synthesis method using an M13-specific primer (Sanger et.al. , 1980) but with modifications that improved transcription fidelity over regions of secondary structure in the template. These included removal of NaCl from the buffer, using reverse transcriptase and optimized ratios of dideox :deoxy nucleotides (1:30A; 2:15C; 1:15G; 2:3T) and performing the reaction at 30°C or greater. Sequences were compiled using a VAX/UMS computer system using the programmes of Staden (1982) with modifications by Dr. T. Kyne.
- cDNA library was constructed with G/C homopolymeric tails of average length 20-30 nucleotides we were unable to obtain clear sequences directly over these tails by the simple subcloning of PstI fragments into Ml3 ventors. Instead we.adopted the strategy of using Bal 31 exonuclease to remove the tails and then subclone random cDNA fragments of the IBDV genome b . blunt-end ligation into Sma I digested Ml3mpl0. The cDNA fragments were initially selected as having originated from the large RNA segment by colony hybridization with a specific probe. Random nucleotide sequences were rapidly sorted and overlapped into a consensus sequence with the aid of computer programmes.
- the final alignment comprised 2950 bp and was constructed from over 60 overlapping sequences .
- No point mutations or rearrangements were found in the overlapping sequences which confirms that the original library construction by randomly primed transcripts followed by reannealing and polymerase elongation was remarkably error-free.
- two problems emerged with this approach. Firstly the subcloning was definitely not random; some regions were sequenced many times whereas cDNA fragments containing the region from nucleotides 2250-2600 could not be subcloned into M13. Secondly the general quality of nucleotide sequence obtained by the chain termination method of Sanger et.al. (1980) was poor due to multiple regions of secondary structure causing premature terminations in the transcriptase reaction.
- the fusion proteins produced by these constructions appear to be particularly stable and has lead to claims of hybrid-protein synthesis up to 30% of the host cell proteins. With suitable inducible promoters sufficient protein is produced to form amorphous aggregates
- Plasmid vectors which have been designed to express only the gene encoded by the cDNA do not appear to produce such high levels of expressed protein.
- pUC, pCQV a gene encoded by the cDNA
- the 5' and 3' terminal sequences of the consensus are defined by the ends of M7 and D6 respectively.
- Structure of the 32Kd antigen is defined by the ends of M7 and D6 respectively.
- Fig. 10 arrows indicate the translational phase in the pUR subclones of D6 and Dl bearing in mind that the initial residue adjacent to the homopolymeric tails has not been included.
- the termination codon at residue 3065 is unambiguous, the N-terminal residue of the 32K antigen is not clear. If the protein is generated from a polycistronic RNA template as implicated for the related IPNV or Drosphila X viruses we would expect initiation at MET 2287 giving rise to a product of 29Kd which is consistent from size estimates. However if the 32Kd protein is generated by processing of a precursor we might expect proteolytic cleavage somewhere before the MET residues, assuming the C-terminus is intact.
- the amino acid sequence derived from the complete nucleotide sequence of the large segment of the IBDV genome is shown in Fig.10. Partial peptide sequencing of purified viral proteins has confirmed these sequences and allowed the positioning of the coding regions of the viral proteins on the large segment of the genome. There is only one translation termination codon at the 3' end of the genomic RNA, and it would appear that the entire genome is expressed as a single polyprotein in which the viral proteins are arranged in the following order: N- 41/37Kd - 28Kd - 32Kd - C. The exact processing mechanism of this large precursor to the
- 15 protein is also expected to encode the larger 52Kd and 41Kd precursors of the 37Kd protein.
- An alternative cleavage site could be the peptide sequence A-X-A-A-S which is repeated three 'times between residues 483-503 r- and also appears at residues 752-756.
- Figure 11 shows Western blot analysis of anti-IBDV
- Figure 12 shows competitive ELISA between anti-IBDV MAbs and a chicken anti-32Kd specific antisera
- MAbs Mouse monoclonal antibodies (MAbs) to IBD virus were prepared by hyper-immunising Balb/C mice with
- the specificity of the MAbs was assessed by Western blotting whole virus (Patent Specification No. PCT/AU84/00256) again modified to detect mouse antibodies by using rabbit anti-mouse Ig (Sera-lab) .
- the majority of MAbs were specific for the 32Kd structural polypeptides of IBD virus, as exemplified by the series 1 and 17 MAbs shown in Fig. 11. Only one series of MAbs, series 6, recognised the 42Kd polypeptide (Fig. 11) and none have yet been obtained that specifically react with the 37Kd polypeptide.
- All the MAbs that were positive for viral polypeptides on Western blots also bound to material on the blots that were of lower mol. wt. than any of the known structural proteins of IBD virus (Dobos, 1979; Patent Specification No. PCT/AU84/00256) and may therefore represent degraded viral proteins.
- the anti-32Kd moloclones, particularly of the 17-80 and 17-83 lineage bound to a large molecule which had an approximate mol. wt. of 55Kd and may represent the unprocessed precursor molecule described earlier.
- the relative antibody activity of the MAbs was assessed by the ELISA and the Immunodot assay; the latter on both denatured and nondenatured virus (Table 1) .
- the specificity of the 17-82 MAbs was investigated in a competitive inhibition ELISA against chicken antisera specific for the 32Kd polypeptide of IBD virus by Western blotting.
- the 17-82 MAbs effectively competed out the chicken anti-32Kd antibodies (Fig. 12) , while the 17-80 and series 6 MAbs were much less effective (Fig. 12) .
- the 17-82 MAbs also completed out a polyspe ⁇ ific chicken antisera, which recognized the 32Kd, 37Kd and 42Kd viral polypeptides on Western blots (data not shown) , indicating that the 17-82 MAbs were against a dominant immunogen on the virus.
- the isotype of the anti-IBD virus MAbs was determined by an ELISA utilising either anti-mouse lambda chain, IgM, IgGl, IgG2a+2b, IgG2b or IgG3 as the second step reagent. All MAbs were of the mouse IgGl class except the 17-82 line MAbs, which were of the IgG2b class.
- the series 6 MAbs were of particular interest as we believe from HPLC analysis of a tryptic and chrymotryptic digest of the 37Kd and 42Kd polypeptides that the latter is the precursor of the former. It would seem likely therefore that the series 6 MAbs recognise the peptide sequence cleaved off during the formation of the major 37Kd structural polypeptide of the Australian type-1 IBD virus.
- MAbs of the 17-80 lineage were used to select recombinant bacterial colonies expressing part or all of the 32Kd polypeptides as described above.
- Figure 13 shows proteins expressed in clones D6, Dl and PI, and IBDV proteins, which were Western blotted and reacted with MAb 17-80.
- the insert of clone PI was constructed by ligating the L6 and D6 inserts via the Apa I restriction site to retain the exact genomic sequence of native IBDV over this region.
- Figure 14 shows clones Dl, D6 and Pi which were lysed by various treatments and the proteins blotted onto nitrocellulose filters, then reacted with either
- MAb 17-80 or MAb 17-82 The expressed proteins were visualised by reaction with [ 125I] Protein A followed by autoradiography.
- Figure 15 indicates the minimum size of precursor polypeptide that has to be expressed for the correct processing of the 32Kd antigen.
- the insert of clone PO that contains the entire coding region of the large segment of IBDV genome, was progressively shortened at the 5' end at specific restriction sites and the resultant fragments were expressed in pPL vector in E.coli. Expressed gene products were Western blotted and reacted with MAb 17-80.
- Figure 16 indicates the regions of the precursor polypeptide that may contribute to the antigenic determinant recognised by the virus neutralising monoclonal MAb 17-82. Undenatured proteins from clones containing precursors of varying sizes were blotted onto nitrocellulose filter and reacted with MAb 17-80 or MAb 17-82.
- a large recombinant molecule spanning bases 425-3145 was constructed by joining the inserts of clone D6 (which encodes the 32Kd protein) and clone L6 (which encodes the 28Kd protein and the major part of the 41/37Kd protein) - full details of both these clones are set out above. L6 and D6 inserts were ligated via the Apa I restriction site to retain the exact genomic sequence of native IBDV over this region.
- This large recombinant molecule (PI) was expressed in pUR plasmids in E.coli and the expressed protein analysed by Western blotting and reaction with MAb 17-80 (Fig.13). The large insert was expected to express a viral polyprotein of M>80Kd (or ⁇ 190Kd as a fusion protein) but instead produced a discrete 32Kd protein that specifically reacted with MAb 17-80.
- the proteins expressed in clone PI were analysed by an immunoblot assay (Fig.14) using a monoclonal antibody (Mab 17-82) that neutralises the virus but does not react with denatured 32Kd viral protein.
- the expressed proteins reacted quite strongly with MAb 17-82, but this reaction was completely abolished when the expressed protein is first denatured in SDS. After denaturation in SDS, the expressed protein reacted strongly with MAb 17-80 which recognises denatured 32Kd protein.
- the genetically engineered polypeptides mimic the immune response of the whole virus particle towards MAb 17-82 and MAb 17-80.
- a larger recombinant molecule (P0) containing the entire coding region of the large RNA segment of IBDV was constructed by ligating the insert of clone PI to the insert of another clone G6 through a common Ndel restriction site.
- P0 was expressed in pEX vector (Stanley and Luzio, (1984)), in E.coli. As in the case of Pi, this resulted in the production of a correctly processed 32Kd polypeptide that reacted with MAb 17-80.
- the 32Kd protein produced in clones PI and P0 might be processed by a virus-specified protease.
- a translation initiation site recognised by E.coli ribosomes may be present within or just before the gene for the 32Kd protein. If this is the case then the introduction of frame shifts within the 28Kd protein should not affect the production of the 32Kd polypeptide in clone P0.
- Frame shifts were introduced by inserting the 1.3Kb Km fragment (Vieira and Messing (1982)) into the EcoRl or Bam HI sites within the gene for the 28Kd protein, or by deleting the EcoRl - Bam Hi fragment. In none of these instances was a 32Kd or higher MW protein produced that reacted with MAb 17-80 on Western blots. This ruled out the possibility that the 32Kd protein is expressed from an independent translation initiation site.
- Fig.15 shows the results obtained by expression in a fusion vector (pPL) that adds on about 7Kd of the XN gene product to the expressed protein.
- the proteins expressed in clones Pi and P0 react strongly with the virus neutralizing MAb 17-82. Since clones PI and P0 produce correctly processed 32Kd protein and other proteins encoded by the large segment it was important to know whether the correct processing of the proteins resulting from the expression of large precursor molecules leads to the expressed polypeptides assuming the correct 3-dimensional structure that is recognised by the virus neutralizing MAb 17-82. Recombinant molecules of various sizes containing the gene for the 32Kd protein and part or whole of the gene(s) for the 28Kd and 52Kd proteins, were expressed in E.coli. The undenatured expressed proteins were blotted onto nitrocellulose filter and reacted with MAb 17-80 or MAb 17-82 (Fig.16). While MAb 17-80 reacted 46 of epitope(s) that induce virus neutralising and/or protective antibody.
- one viable approach to producing the correctly processed and folded antigens is to express the entire coding region or precursors retaining the 32Kd, 28Kd and a substantial portion of the 52Kd precursor proteins.
- the antigens produced by this method can be readily purified by affinity chromatography using monoclonal antibodies, or by engineering specific sequences at the termini of the expressed antigens.
- Another approach is to express the complete gene or fragments thereof for the 32Kd and/or the 52Kd protein.
- a ubsequent refolding step may or may not be required.
- This approach is quite feasible since we have previously demonstrated (International Patent Application PCT/AU84/00256) that the viral 32Kd protein isolated from SDS-polyacrylamide gel can refold and when injected into chickens produce virus neutralizing and protective antibodies.
- an unfused protein of 30Kd produced by the expression of the Ahall - Pst 1 fragment of the 32Kd gene in pCAV2 vector reacts with the virus neutralizing MAb 17-82.
- the protein expressed from the gene for the 52Kd precursor of the 41Kd and 37Kd structural proteins also reacts with the virus neutralising MAb 17-82.
- fusion proteins in which an enzymic or chemical cleavage site has been engineered at the junction between the IBDV and host proteins.
- the levels of expression of fusion proteins are very high 45 with proteins expressed in all the constructs, the virus neutralizing MAb 17-82 only reacted with proteins expressed in clones in which the substantial portion of the 52Kd precursor of the 37Kd protein is retained (Fig.16).
- Fig.15 clearly shows that the correct processing of the 32Kd protein does not require any portion of the 52Kd protein or even the extreme N-terminal portion of the 28Kd protein.
- the correct processing of the 32Kd protein alone does not ensure recognition by MAb 17-82, and a portion of the 52Kd precursor protein may be directly or indirectly involved in the process.
- the antigenic determinant recognised by the virus neutralizing MAb 17-82 may consist of a discontinuous epitope made up of contributing regions from both the 32Kd and 41/37Kd proteins. Fusion proteins from clones D6 and Dl in the undenatured state, react weakly, but quite specifically with virus neutralising MAb 17-82. Unfused protein produced by the expression of the Aha II - Pst 1 fragment of the 32Kd gene, also react with MAb 17-82. Thus the 32Kd protein or part thereof, is recognised albeit weakly by MAb 17-82.
- the gene encoding this region was expressed in pEX vector in E.coli.
- the undenatured expressed protein reacted strongly with MAb 17-82, indicating that the 52Kd precursor also contained an epitope(s) recognised by the virus neutralising MAb. It is possible that an interaction between the 32Kd and the 41/37Kd structural proteins may be involved in formation and the expressed protein can be readily purified by affinity chromatograph .
- the IBDV protein can be recovered by enzymic or chemical cleavage of the purified fusion protein.
- HUDSON P., JOHN, M. , CRAWFORD, R. , HARALAMBIDIS, J., SCANLON, D., GORMAN, J. , TREGEAR, G. , SHINE, J., and NIALL, H. (1984) EMBO J. 3_, 2333-2339.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A recombinant DNA molecule comprising a nucleotide sequence substantially corresponding to all or a portion of IBDV RNA, particularly the IBDV RNA segment of approximately 3400 b.p. In particular, a DNA molecule coding for all or a part of at least one structural protein of IBDV, for example, the 32Kd and/or the 41/37Kd structural proteins. Synthetic peptides or polypeptides, and fused polypeptides, prepared by expression of host cells containing these DNA molecules are also disclosed.
Description
"CLONING AND EXPRESSION OF HOST-PROTECTIVE IMMUNOGENS OF IBDV"
This invention relates to the cloning and characterisation of the infectious bursal disease virus (IBDV) genome, to the identification of cloned genes for host-protective antigens of IBDV, to the expression of cDNA inserts encoding the whole or part of host-protective antigens of IBDV in E.coli or other host cells, and to the use of the expressed antigens in the production of virus neutralizing antibodies in chickens. The invention further relates to the production of an effective sub-unit vaccine against IBDV utilising the expressed antigens, as well as to the use of the expressed antigens in diagnostic tests, assays and the like.
In one particularly preferred aspect, this invention relates to a method for the use of recombinant DNA techniques in the production of "correctly" processed antigens of IBDV. The production of such "correctly" processed antigens is of particular importance in ensuring, for example, that these antigens may be effectively used as vaccine components for the production of neutralising and protective antibodies.
The polypeptides of an Australian strain (002-73) of IBDV have recently been characterised. In prior International Patent Specification No. PCT/AU84/00256, it is disclosed that the 32Kd structural protein is a major immunogen of IBDV, and produces antibodies in chickens that neutralize the virus in vitro and protect the chickens from IBDV infection.
Further work has now led to the characterisation and molecular cloning of the genome of IBDV strain 002-73, and this genome has been shown to consist of two segments of double-stranded (ds) RNA which are approximately 3400 b.p. (MW 2.06 x 10 ) and 2900 b.p. (MW 1.76 x 10 ) long, respectively. Xn vitro translation studies show that the large RNA segment codes for three major structural proteins, including the 32 Kd host-protective antigen previously identified. A novel method for the cloning of long double-stranded RNA molecules has been developed and used to clone the entire genome of IBDV. Molecular hybridization and expression studies involving cloned cDNA inserts have allowed the identification of the region of the IBDV genome that codes for the 32 d host-protective antigen. Cloned genes encoding the entire or part of this antigen have been sequenced and expressed in E.coli. In addition the immunogenicity in chickens of the expressed polypeptides has been tested, as well as their ability to produce virus neutralising antibodies.
Initial work in this regard has lead to the production of the 32Kd host-protective antigen of IBDV in the form of fusion proteins. The test results show that the fusion proteins are highly im unogenic and produce antibodies that recognise denatured 32Kd
protein. These antibodies, however, have weak ELISA and virus neutralising titres. The fusion proteins react strongly with MAb 17-80 (monoclonal antibody that recognises denatured 32Kd viral protein) , but weakly with the virus neutralising MAb 17-82. These results suggest that these genetically engineered fusion proteins may not have the correct three-dimensional structure necessary for the production of virus neutralising and protective antibodies, or that other viral proteins possess epitopes or are important in the formation of epitopes involved in the neutralisation of whole virus.
Further work has shown that a monoclonal antibody (MAb 17-82) , that neutralises the infectivityof IBDV, recognises an epitope encoded within the. gene for the 52Kd precursor protein; a protein processed into the 41Kd and 37Kd structural proteins of IBDV. The expressed polypeptide from the 52Kd region that reacts with MAb 17-82, does not contain epitopes recognised by the monoclonal antibody specific for the 32Kd structural protein (MAb 17-80) .
According to one aspect of the present invention, there is provided a recombinant DNA molecule comprising a nucleotide sequence substantially corresponding to all or a portion of IBDV RNA, particularly the IBDV RNA segment of approximately 3400 b.p. Preferably, the nucleotide sequence codes for all or part of at least one structural protein of IBDV. In one particular aspect of the invention, the DNA molecule is capable of being expressed as a polypeptide displaying antigenicity substantially corresponding to the 32Kd or 41/37 d structural protein of IBDV.
By way of exemplification of this aspect of the invention, the nucleotide sequence may be character¬ ised by at least a portion thereof having the base sequence substantially as shown in Figure 10 hereinafter or one or more portions of said base seqμence.
The complete nucleotide sequence of the large segment of the IBDV genome and the amino acid sequence derived from it are shown in Fig.10.
Translation, in vitro, of the IBDV large segment genomic RNA in rabbit reticulocyte and wheat germ cell-free systems has led to the synthesis of discrete polypeptides identical in size to the viral proteins although there is only one stop codon at the 3' end of the large segment of the IBDV genome. While the rabbit reticulocyte and wheat germ cell-free systems may contain protease(s) which help to process viral poly-proteins, it would appear more likely that one of the polypeptides encoded by the IBDV genome is a specific protease. Further work in this regard has enabled the production of correctly processed 32Kd or 41/37Kd protein of IBDV instead of the fused proteins described above.
Accordingly, in a particularly preferred embodiment of this invention, there is provided a recombinant DNA molecule comprising a nucleotide sequence coding for all or part of the 32Kd structural protein or the 52Kd precursor protein of IBDV, together with further portion(s) of the 3400 b.p. segment coding for further polypeptides or proteins to correctly process said 32Kd or 41/37Kd structural protein. Expression of this molecule leads to the expression of the 32Kd or 41/37 Kd structural protein as a correctly
processed protein. Such a molecule may encode both the 32Kd structural protein as well as additional polypeptides or proteins, including proteases, required ; to correctly process the 32Kd structural protein.
5
It will be appreciated that the nucleotide sequence of this aspect of the invention may be obtained from natural, synthetic or semi-synthetic sources, or by manipulation of the natural material; furthermore, this
10 nucleotide sequence may be a naturally-occurring sequence, or it may be related by mutation, including single or multiple base substitutions, deletions, insertions and inversions, to such a naturally-occurring sequence, provided always that the DNA molecule comprising such a sequence is capable of being expressed as a polypeptide displaying the antigenicity of one or more structural proteins of IBDV.
The nucleotide sequence may have expression
20 control sequences positioned adjacent to it, such control sequences being derived either from IBDV nucleic acid or from a heterologous source.
This invention also provides a recombinant DNA 2 molecule comprising an expression control sequence having promoter sequences and initiator sequences, and a nucleotide sequence coding for all or part of at least one structural protein of IBDV.
30 In yet another aspect, the invention provides a recombinant DNA cloning vehicle capable of expressing all or part of at least one structural protein of IBDV, comprising an expression control sequence having promotor sequences and initiator sequences, and a
nucleotide sequence coding for all or part of at least one structural protein of IBDV.
In a further aspect, there is provided a host cell containing a recombinant DNA cloning vehicle and/or a recombinant DNA molecule as described above.
In yet further aspects, there are provided polypeptides displaying IBDV antigenicity which can be produced by a host cell transformed or infected with a recombinant DNA cloning vehicle as described above. Such expressed polypeptides may comprise all or part of at least one structural protein of IBDV as derived from the base sequence substantially as shown in Figure 10 or one or more portion(s) of the said sequence. Such polypeptides can be isolated from the host cell, and if necessary purified to provide the polypeptide substantially free of host cell or other proteins. Where the expressed polypeptides are in the form of a fused polypeptide, they may be cleaved to remove the "foreign" peptide portion.
It will be appreciated that such expressed polypeptides as described above may be constructed by permutation and combinations of portions of the nucleotide sequence presented in Figure 10.
The present invention also extends to synthetic peptides or polypeptides displaying the antigenicity of all or a portion of at least one structural protein of IBDV, particularly the 32Kd and/or 41/37Kd structural proteins.
As used herein, the term "synthetic" means that the peptides or polypeptides have been produced by
chemical and/or biological means, such as by means of chemical synthesis or by recombinant DNA techniques leading to biological synthesis. Such polypeptides can, of course, be obtained by direct expression by a host-cell of a correctly processed and folded protein, or by cleavage of a fused polypeptide produced by a host cell and separation of the desired polypeptide from additional polypeptide coded for by the DNA of the host cell or cloning vehicle by methods well known in the art. Alternatively, once the amino acid sequence of the desired polypeptide has been established, for example, by determination of the nucleotide sequence coding for the desired polypeptide, the polypeptide may be produced synthetically, for example by the well-known Merrifield solid-phase synthesis procedure [Marglin and Merrifield, (1970)] .
It will be 'appreciated that polypeptides displaying antigenicity characteristic of structural proteins of IBDV will have utility in serological diagnosis, and in the preparation of single or multivalent vaccines against IBDV by methods well known in the art of vaccine manufacture. Further details of such vaccines, and of methods of use thereof, as well as of quantitative and qualitative assays, are disclosed in International Patent Specification No. PCT/AU84/00256.
The following detailed description relates to the characterization and molecular cloning of the genome of IBDV strain 002-73. In the accompanying diagrams:
Figure 1 shows electrophoresis of IBDV RNA translation products synthesised in rabbit reticulocyte lysate, particularly the MW of translation products and coding assignments of IBDV RNA segments (i) MW standards; (ii) unfractionated IBDV RNA; (iii) large segment of IBDV RNA; (iv) small segment of IBDV RNA.
Figure 2 is a map of cloned inserts covering the entire large RNA segment of IBDV.
Materials and Methods
Materials and their sources are lenow fragment of
DNA poly erase 1, SI nuclease, DNase 1, and RNase A (Boehringer) ; rabbit reticulocyte lysate, [α- 32P]ATP, [γ- 32P] ATP, [35S]methionine, and PstI (Amerisham) ;
RNase-free sucrose, DNA polymerase 1, and wheat germ lysate (Bethesda Research Laboratories) ; RNase-free
Pronase (Calbiochem) ; agarose and lysozyme (Sigma) ; low melting point agarose and SDS (Bio-Rad) , diethylpyrocarbonate and acridine orange (Merck) ; nitrocellulose filters and NA45 membrane filters (Schleicher and Schuell) ; reverse transcriptase (RTase) (Life Sciences Incl, St. Petersburg, Fla.); terminal transferase (Ratliffe, Los Alamos, N.M.); RNasin (Promega Biotech, Madison, Wise). Random primers were prepared from sheep DNA by the method described by Taylor et al., (1976). UK bovine rotavirus ds RNA was prepared by Dr. M. Dyall-Smith. Virus: IBDV strain 002-73 was first reported by Firth (1974) in commercial chicken flocks in Australia and confirmed as IBDV at the Central Veterinary Laboratory, Weybridge, U.K. The virus was routinely passaged in 4- to 6-week old SPF White Leghorn chickens, isolated from bursas 3 days
after infection, and purified by successive fractionations on sucrose and CsCl gradients.
Isolation and purification of IBDV RNA Homogenates of fresh infected bursas ,were spun at 17,000 g for 15 minutes at 0°. The clear supernatant was layered on top of 2-ml sucrose cushions (40%) and the virus particles were pelleted through the cushions in a Beckman SW40 rotor at 22,000 rpm at 2° for 2.5 hours. The pellets were suspended in 10 mM Tris. pH 7.5, 10 mM NaCl, 10 mM EDTA, 0.2% SDS, and 0.1% diethylpyrocarbonate and digested with RNase-free Pronase (1 g/ml) for 1 hour at 37°, The solution was extracted with phenol and chloroform (1:1) and the RNA in the aqueous phase recovered by precipitation with ethanol. The ds viral RNA was purified from the chicken cellular RNA by differential salt precipitation (Diaz-Ruiz and Kaper, 1978) .
Individual RNA or DNA segments were isolated from agarose gels by electrophoresis onto NA45 membrane filters followed by elution in 1M NaCl and 0.05 M arginine at 70°. Alternatively, RNA bands were excised from low melting point agarose slab gel and melted' (70°) in 5 mol. of low salt buffer containing 0.5% SDS. The solution was extracted with phenol and the RNA in the aqueous phase precipitated with ethanol.
Hybridization probes. IBDV RNA was labeled with [γ-32P] following mild alkaline digestion (Goldbach et al. 1978) . cDNA probes were prepared from denatured ds RNA using random primers to initiate cDNA synthesis in the presence of RTase. The RNA template was then destroyed by digestion with
NaOH. Nick translation of cloned DNA fragments was carried out essentially as described by Rigby et al. (1977) . All radioactively labeled probes were purified from unreacted isotopes by precipitation (3x) from 2 M ammonium acetate and isopropanol at room temperature.
Translation of IBDV RNA in vitro.
IBDV RNA (1-2 μg) in 3 μl of 10 mM phosphate, pH 6.8 was heated at 100° for 2 minutes and snap chilled in dry ice/ethanol. Methylmercurie hydroxide (1 μl of 40 mM) was then added and the mixture left at room temperature for 10 minutes. 8-Mercaptoethanol (1 μl of 700 mM) and 1 μl of RNasin (25 units) were added and the solution was incubated for a further 5 minutes at room temperature. Aliquots (1 μl) were transferred to tubes containing 5 μCi of [ 35S.methionine (dried down) and 30 μl of rabbit reticulocyte lysate and the solution was incubated at 30° for 1 hour. The reaction mixture was • reacted in succession with chicken antiserum, rabbit anti-chicken IgG, and protein A-Sepharose (Pharmacia) .
The protein A-Sepharose-antigen-antibody complex was washed extensively with phosphate-buffered saline containing 0.1% NP-40 and then boiled in buffer containing 2% SDS. The protein A-Sepharose was spun down and the translated proteins in the supernate were analysed by polyacrylamide gel electrophoresis (12.5% gel) . The gel was then treated with AMPLIFY (Amersham) , dried and exposed to Fuji RX film with intensifying screen (Dupont Cronex Lightening Plus AA) .
Synthesis of ds cDNA from ds RNA.
IBDV RNA (5 μg) in 9 μ; pf 5mM phosphate buffer, pH 6.8, was heated at 100° for 2 minutes and then snap frozen. After the RNA had thawed 1 μl of 100 mM
methylmercuric hydroxide was added and the mixture left at room temperature for 10 minutes. Two microliters of RNasin (50 units) and 4 μl of 700 mM β-mercaptoethanol were then added and the mixture was left at room temperature for a further 5 minutes. Ten microliters of random primers (50 μg) , which had been separately denatured by boiling and snap chilling, was then added to the mixture to prime cDNA synthesis. The mixture (100 μl final volume) contained RTase (50 units) and other reactants required for cDNA synthesis. Following incubation at 42° for 2 hours the RNA template was destroyed by digestion with NaOH, and the cDNA purified by gel filtration. Complementary cDNA fragments were annealed in 0.3 M NaCl at 65° for 2 hours following initial heating at 90° for 3 minutes. The solution was then allowed to cool gradually to room temperature over 1 hour. The annealed cDNA segments were repaired and chains extended with DNA polymerase 1. The ds cDNA chains were further extended with RTase, treated with DNA ligase and SI nuclease, and finally purified by gel filtration.
Cloning of IBDV ds cDNA.
The ds cDNA was C tailed with terminal transferase, annealed to G-tailed Pst-cut pBR322 (New England
Nuclear) , and cloned in Escherichia coli RRl cells. The recombinant colonies were hybridized with radioactive probes made from IBDV RNA segments and autoradiographed. Biological containment levels specified by the Australian Recombinant DNA Monitoring Committee were used.
Isolation of plasmid DNA.
Plasmid DNA was isolated essentially by the Ish-Horowicz and Burke (1981) modification of the method described by Birnboim and Doly (1979) with the following further modifications. RNase digestion was carried out concommitantly with lysozyme treatment, and the plasmid DNA was purified from RNA breakdown products by precipitation from polyethylene glycol (6.5% PEG, 0.8 M NaCl, 0°, 1 hour) .
Colony hybridization.
The recombinant colonies were hybridized with radioactive probes as described by Grunstein and Hogness (1975) . The solution used for prehybridization and hybridization contained 5X Denhardt's solution, 10 mM
HEPES (pH 7.0), 0.1% SDS, 3X SSC, 10 μg/ml E. coli tRNA, and 18 μg /ml sonicated and denatured herring sperm DNA. The filters were prehybridized at 65° for 2 hours, and then hybridized with radioactive probes for 16-20 hours at 65°. The filters were washed 4 X 30 minutes with 0.5 X SSC,0.1% SDS at 65°, and then autoradiographed using Fuji RX film and intensifying screen.
Results 1. Isolation and purification of RNA. The RNA isolation procedure described above is simple and rapid, and results in a high yield of good quality RNA. A low-speed spin of the bursal homogenate followed by sedimentation of the virus particles through a 40% sucrose cushion resulted in the removal of virtually all the cellular DNA and over 90% of the cellular RNA. Following digestion with Pronase and extraction with phenol and chloroform, the total RNA was fractionated by
differential salt precipitation (Diaz-Ruiz and Kaper, 1978) . The cellular ss RNA was precipitated from 2 M LiCl and the viral ds RNA in the supernatant could be further purified from low MW contaminants and any contaminating DNA by precipitation from 4M LiCl.
2. Physico-chemical characterization of the viral genome. To determine whether the RNA of the Australian isolate IBDV 002-73 is double stranded, viral RNA which had not been totally purified from single-stranded cellular RNA was electrophoresed under nondenaturing conditions, stained with acridine orange, and the nucleic acid bands were visualized on a uv transilluminator. The DNA standards, ds UK bovine rotavirus RNA segments, and the two segments of IBDV RNA in the upper part of the gel appeared as bright green bands as expected of ds nucleic acids (Lerman, 1963), while the single-stranded cellular RNA near the bottom of the gel appeared bright red (Blake and Peacocke, 1968) . Moreover, under RNase A-digestion conditions that completely destroy 28 S and 18 S rRNA the two segments of IBDV RNA remained intact when electrophoresed under nondenaturing conditions. Thus, the genome of IBDV strain 002-73 consists of two segments of ds RNA as has been shown to be the case for strain Cu-1 (Muller et al, 1979) and a strain isolated at the Central Veterinary Laboratories, Weybridge, U.K. (Todd and McNulty, 1979) .
When electrophoresed under nondenaturing conditions the two segments of IBDV RNA appear to be 3825 and 3400 bp, respectively, when compared with DNA standards. These values correspond to MW of 2.52 x 10 and 2.2 x 10 , respectively, for the two segments. When compared
under nondenaturing conditions with ds RNA segments of UK bovine rotavirus, the sizes of which were obtained by electron microscopy (Rixon et al, 1984) , the two segments of IBDV ds RNA appear to be about 3400 bp (MW 2.06 x 106) and 2900 bp (MW 1.76 x 106) , respectively.
3. Translation, in vitro, of IBDV RNA. The ds RNA has to be extensively denatured for any in vitro protein synthesis to take place. Heating at 100° followed by snap chilling in dry ice/ethanol was not sufficient, and heating the RNA in 90% di ethylsulfoxide gave inconsistent results. The best results were obtained when the heat-denatured RNA was further denatured in 10 mM methylmercuric hydroxide. Even after these treatments the amount of radioactivity incorporated into TCA-precipitable material was only between 10 and 20% of that obtained when translating similar amounts of rotovirus ss RNA or globin mRNA.
Immunoprecipitation of the translation product shows that total IBDV RNA codes for six polypeptides of Ca. MW 90Kd, 52Kd, 4lKd, 32Kd, 18Kd, and 16Kd (Fig. 1 (ii) . The larger RNA segment, purified by gel electrophoresis, produces all the translation products except the 90-Kd polypeptide (Fig. 1 (iii) . When the smaller RNA segment, which we have not been able to completely purify by gel electrophoresis, is translated in vitro traces of all the translation products are seen but the 90-Kd protein is consistently the most prominent one (Fig. 1 (iv) . Since this 90-Kd protein is consistently absent among the translation products of the larger RNA segment it would appear that all the IBDV proteins except the 90-Kd protein are encoded by the larger RNA segment.
4. Molecular cloning of IBDV ds DNA. To overcome problems encountered in the synthesis of cDNA covering the entire IBDV genome an alternative method was developed for the cloning of long ds RNA molecules. The ds RNA was denatured in methylmercuric hydroxide and random primers were used to initiate cDNA synthesis on both strands of the RNA simultaneously in the presence of RTase. The RNA was then destroyed and complementary cDNA strands were allowed to reanneal. DNA polymerase 1 was used to repair and extend the cDNA chains, which were then extended further with RTase. The ds cDNA molecules were then treated with DNA ligase followed by SI nuclease. The ds cDNA molecules were C tailed and annealed to G-tailed pBR322, and used to transform E.coli RRl cells.
Recombinant colonies were hybridized with radioactive probes made from the large or small segment of IBDV RNA, and 200 colonies positive to each of the probes were randomly selected for further characterization. The positive colonies were screened for plasmid size by electrophoresing colony lysates on agarose mini-gels. A few of these colonies, positive to the large segment probes, were grown up in 5 ml L broth for plasmid DNA isolation. The plasmids were digested with PstI and the sizes of the inserts determined by electrophoresis. These inserts of defined size were "nick translated" and used separately to probe identical sets of positive colonies. Inserts from clones D6 (1100 bp) , L6 (1900bp) , and M7 (450 bp) hybridized with three basically different sets of colonies. Inserts from clone G2 (1600 bp) hybridized to colonies which previously hybridized either with D6 or L6 probe but not with both. Similarly, a N9 insert (950 bp) hybridized
with colonies which were positive either to the L6 or M7 probes but not to both. From the sizes of the insert and the extent and ability to cross-hybridize with colonies positive to the large RNA segment it was possible to construct a tentative map to show that overlapping cDNA fragments covering the entire large RNA segment had been cloned (Fig. 2) , and the relative positions of all the positive colonies could be determined on this map.
The following detailed description relates to the expression in E.coli of cDNA fragments encoding the gene for the host-protective antigen of IBDV. In the accompanying diagrams:
Figure 3 shows some E.coli colonies expressing proteins positive to a monoclonal antibody (Mab 17-80) that reacts with denatured 32Kd protein of IBDV.
Figure 4 shows proteins from E.coli colonies subjected to electrophoresis and (a) stained with Coomassie Blue, or (b) Western blotted and reacted with MAb 17-80. Arrows 1 and 2 indicate the positions of fusion protein and β-galactosidase, respectively. Samples are (i) HB 101 cells, (ii) HB 101 with pUR 290, (iii) - (viii) some recombinant clones that were identified as possible positives by reaction with MAb 17-80 (Fig.3).
Figure 5 shows (a) the position of the insert from clone D6 on the large segment of IBDV genome; (b) the restriction map of the inserts from clones D6 and Dl.
Figure 6 shows the determination of optimum conditions for expression of fusion proteins. Cells were grown to an O .Ω . coo/.nU of 0.2, (i) then grown further with or without induction with 1.5mM IPTG, (ii) 1.5hr, (iii) 1.5hr + IPTG, (iv) 3.0hr, (v) 3.0hr + IPTG, (vi)
4.0hr, (vii) 4.0hr + IPTG. Samples were electrophoresed and the gel was stained with Coomassie blue. The arrow indicates the position of the fusion protein.
Figure 7 shows affinity purification of fusion protein from clone Dl. (i) Total E.coli protein; (ii)-(vii) fractions eluted from column.
Figure 8 shows affinity purified proteins from clones Dl and D6, subjected to electrophoresis and stained with Coomassie blue (a) , reacted with anti-0- galactosidase (b) , and reacted with anti-32Kd-monoclonal antibody (c) .
Figure 9 shows Western blot analysis of sera from unprimed (1°) or primed (2°) chickens injected with fusion proteins from clones Dl or D6 in Freund's adjuvant. Sera obtained prior to vaccination (0) , 3 weeks after injection of fusion proteins (3) , or 4 weeks after a second injection of fusion proteins (7) .
Materials and Methods
The materials and their sources are: DNase 1, lysozyme, agarose, BSA, isopropyl β-D-thiogalactoside (1 PTG) and l-ethyl-3(3-dimethylaminopropyl) carbodiimide (Sigma) : goat anti-mouse IgG horse radish peroxidase conjugate (GAM HRP) , goat anti-rabbit IgG horse radish peroxidate conjugate (GAR HRP) , and HRP colour in -t oe developing reagent (BioRad) : α[ Pi dATP, [ I] Protein
A and Pst 1 (amersham) ; nitrocellulose filters and MA45 membrane filters (Schleicher and Schuell) ; CH-Sepharose 4B (Pharmacia) : DNA polymerase (Boehringer) ; rabbit anti-mouse IgG (Dako immunoglobulins (Denmark) . Monoclonal antibodies against IBDV were produced and characterized as described below.
IBDV strain 002-73 was grown and isolated as described earlier.
Colony and Southern blot hybridization, isolation of plasmid DNA, production of hybridization probes, agarose gel electrophoresis, polyacrylamide gel electrophoresis (Lae li) and autoradiography were performed as described earlier.
Immunoassay of expressed proteins in recombinant colonies:
Recombinant colonies were grown (37°) on nitrocellulose filters on LB plates containing 30 μg/ml ampicillin. All subsequent steps were carried out at room temperature. The nitrocellulose filters were placed in a chloroform atmosphere on Whatman No. 3 paper saturated with 1% SDS for 30 minutes to 1 hour. The filters were rinsed with 50 mM Tris-HCl (pH 7.5), 150 mM NaCl (TBS) to remove cell debris, and then incubated for 1 hour with shaking in TBS containing 3% BSA, 5mM MgCl-, lμg/ml Dnase and 40 μg/ml lysozyme. This was followed by incubation for 1 hour in supernatant from monoclonal antibodies. The filters were then washed for 10 minutes in TBS, 10 minutes in TBS-0.1% NP40 and finally for 10 minutes in TBS. Sometimes the filters were reacted with a second antibody (rabbit anti-mouse IgG) in TBS containing 3% BSA, and washed as described earlier.
Initial experiments the recombinant colonies expressing the desired protein were identified by using [ 125I]
Protein A. After reactions with the antibodies the filters were incubated with [ 125I] Protein A m TBS containing 3% BSA. The filters were then washed for 90 minutes in 50 mM Tris-Hcl (pH 7.5), 1M NaCl, 5mM EDTA, 0.25% gelatin, 0.4% Sarkosyl, and autoradiographed as described earlier. In later experiments the filters after reaction with monoclonal antibody and washing were reacted with goat anti-mouse IgG horse radish peroxidase conjugate or with goat anti-rabbit IgG horse radish peroxidase conjugate (when amplified with a second antibody) in TBS-3% BSA for 1 hour. The filters were then washed for 20 minutes in phosphate buffered saline, followed by colour development using the HRP colour developing reagent as described by BioRad.
Assay of small amounts of proteins isolated from E.coli cells: E.coli cultures (0.8 ml in Eppendorf tubes) were grown in L broth containing ampicillin for 1 - 2 hours, induced with IPTG if required, and the cells collected by centrifugation.
If the proteins were to be analyzed by polyacrylamide gel electrophoresis, the cell pellet was suspended directly in the loading buffer containing 60mM Tris-Hcl (pH 7.5), 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.001% bromophenol blue, and boiled for two minutes. 50μl aliquots were loaded in duplicate on two gels. Proteins on one gel were stained with Coomassie blue, and proteins on the duplicate gel transferred to nitrocellulose filter.
For quick immunoassays of the isolated protein, the cell pellets were suspended in 300μl TBS buffer containing 40μgml lysozyme (0°, 15 minutes) and then SDS was added to 1% and the solution left at room temperature for 30 minutes. Alternatively, the cell pellet was suspended in 300μl TBS buffer and sonicated. In either case, cell debris were removed by centifigation, and lOOμl of the supernatant blotted onto nitrocellulose filter using Schleider and Schuell Manifold apparatus. The filter was then immunoassayed as described earlier for recombinant colonies.
Western blotting
Proteins electrophoresed on acrylamide gels were transferred to NC filters with Bio-Rad Transblot apparatus using buffers and protocol described by Bio-Rad. Proteins of interest were detected by immunoassaying the filter as described earlier.
Purification of the expressed fusion protein
The fusion protein was purified by affinity chromatography (Ullmann, 1984) .
Vaccination of chicken with fusion proteins Preparations of affinity purified fusion proteins
Dl and D6 were emulsified in an equal volume of Freund's complete adjuvant and 1 ml injected intramuscularly into a series of adult White Leghorn chickens. The vaccines were injected into both specific pathogen free (SPF) chickens and chickens that had previously (> 8 weeks) been sensitized by inoculation with live IBDV. The chickens were revaccinated three weeks later with the respective fusion proteins emulsified in Freund's
incomplete adjuvant and bled at weekly intervals throughout.
Results and Discussion 1. Subcloning of cDNA inserts into pUR vectors:
The large segment of IBDV RNA encodes three major structural proteins including the 32Kd host-protective antigen. cDNA inserts hybridizable to the large segment of IBDV RNA were recovered from the cDNA library by digestion of the "mixed" plasmids with Pst 1, and the "mixed" inserts were subcloned into the Pst 1 site of pUR expression vectors 290, 291 and 292, (Ruther and Muller-Hill, 1983) and these were used to transform E.coli HB101 cells. These three vectors together contain restriction sites in all three frames at the 3' end of the lacZ gene. Insertion of cDNA in the proper cloning site leads to a fusion protein of active β-galactosidase and the peptide encoded by the forein cDNA.
2. Identification of colonies expressing the 32 Kd polypeptide or parts of it
Recombinant colonies containing cDNA inserts hybridizable to the large segment of IBDV RNA were grown on nitrocellulose filters on LB plates containing ampicillin (30 μg/ml) . The colonies were induced with isopropyl β-D-thiogalactopyranoside (IPTG) and then lysed by placing the filters on Whatman No. 3 paper soaked in 1% SDS in a chloroform-saturated atmosphere. After blocking with BSA, the filters were reacted with monoclonal antibodies that recognize the 32Kd , polypeptide on Western blots (MAbsl7-80) . The filters were then reacted with rabbit anti mouse IgG followed by [ 125I] Protein A and autoradiographed. A number of
possible positive clones expressing proteins that react with monoclonal antibody specific to the 32 Kd structural proteins could be seen on the autoradiograph (Fig. 3) . The protocol was modified for later experiments. After incubation with the monoclonal antibody the filter was reacted with goat anti-Mouse IgG Horse Radish Peroxidase (BioRad) and subjected to colour development.
A total of 20 possible positives were selected for further characterization. These colonies were spread on LB plates and resultant individual colonies were reprobed with monoclonal antibodies specific for the denatured 32 Kd protein. Only three of the original possible positives expressed polypeptides that reacted with the monoclonal antibody.
3. Characterization of the expressed proteins
The expressed proteins were characterized by polyacrylamide gel electrophoresis and Western blotting. The cells grown in Eppondorf tubes in L broth were spun down and boiled in 2% SDS for 2 minutes and loaded in duplicate on two separate gels. After electrophoresis one gel was stained with Coomassie blue, and proteins from the other gel were electroblotted onto nitrocellulose filter and probed with monoclonal antibody specific for the 32 Kd polypeptide.
Examination of the stained gel showed no prominent polypeptide band larger than β-galactosidase (Fig. 4a) , but the Western blot of the duplicate samples showed very prominant polypeptide bands larger than β-galactosidase (Fig. 4b) . The expressed fusion proteins from all the positive clones were of the same
size, but some clones produced more of the expressed proteins than others, and this allowed us to identify clones that grew faster and expressed more of the fusion protein.
Identification of the region of the IBDV genome that codes for the 32 Kd host-protective antigen
The cDNA inserts, obtained by digestion with Pst 1, from all the positive clones were of identical size of about 450 b.p. These inserts were "nick-translated" and hybridized with a series of cDNA clones that contain a network of overlapping fragments covering the entire large segment of the IBDV genome. The inserts from the expressing clones, in every case, hybridized specifically with clone D6 which spans the 3' end of the large segment of IBDV RNA (see Fig. 5a) and other cDNA clones containing inserts of varying sizes from the same region of the IBDV genome.
The inserts from the expressing clones had identical restriction maps and were of identical size. Therefore one clone, Dl, that grew well and expressed the fusion protein to a high level, was selected for further studies. The insert of Dl is present in the vector pUR 290. Comparison of the restriction maps
(Fig. 5b) of inserts from clones Dl (450 b.p.) and D6 (1100 b.p.) show that the Dl insert is situated towards the 3' end of the D6 insert. Sequencing studies (see later) confirm the location of the Dl insert and show that it lacks the initiation and termination codons, and constitutes about 50% of the 32 Kd host-protective antigen. The insert of clone D6 on the other hand is large enough to encode the entire 32 Kd polypeptide. Therefore, the insert from clone D6 has been subcloned
in the pUR vectors and clones expressing fusion proteins larger than that from clone Dl have been obtained.
A clone containing the D6 insert in pUR vector 291 5 which grows well and expresses the fusion protein to a high level was selected for further studies. Clone Dl (450 b.p. insert) and clone D6 (1100 b.p. insert) both produce fusion proteins in which the C-terminal polypeptides fused to β-galactosidase react strongly 10 with monoclonal antibodies specific for the 32 Kd host-protective antigen. Clones Dl and D6 have been used for all subsequent studies.
Optimum conditions for expression 15 The optimum conditions for the expression of the fused proteins were as follows (Fig. 6) . Cells were grown in L Broth in presence of ampicillin (30 μg/ml) to an O.D. 660 of 0.2 and then induced with 1.5 mM IPTG for 4 hours. There was no significant synthesis of the
20 fused proteins at 3 hours after start of induction, and there was a dramatic increase in synthesis of the fused proteins after four hours of induction. Induction for longer periods or at higher cell concentrations did not result in higher yields of the fused protein.
25
Purification of the fusion proteins
The fusion proteins from clones Dl and D6 were affinity purified as described by Ullmann (1984) . When pUR vectors are used for expression the β-galactosidase
30 moiety of the fusion protein is enzymatically active and will bind to a substrate for β-galactosidase (Ullmann
(1984)). E.coli cell lysate, in buffer containing 1.6M
NaCl, was passed through an affinity column containing
CH Sepharose coupled to p-aminophenyl-
35
β-D-thiodalactoside and equilibrated with the same buffer. Only β-galactosidase or proteins fused to it will bind to the affinity column under these conditions. The bound protein was quantitatively eluted with lOOmM borate, pHlO. The purification of fusion proteins from clone Dl is shown in Fig. 7.
The highly purified fusion proteins (Dl and D6) and free β-galactosidase (Fig. 8a) were recovered at a fairly high concentration of ca. 1 - 2 mg/ml, and yielded up to 20 g of affinity purified protein per litre of culture. However, the fusion protein was subject to proteolytic degradation as evidenced by the presence of substantial amounts of polypeptides having electrophoretic mobilities similar to or faster than β-galactosidase. Three bands are seen in affinity purified proteins from clones D6 and Dl. All of the bands react with anti-β-galactosidase IgG (Fig. 8b) , while only bands la and lb, from D6 and Dl respectively, react with the anti-32 Kd^monoclonal (Fig. 8c) .
However, it is mainly the C-terminal IBDV protein that is substantially degraded. This degradation of the IBDV expressed protein does not seem to be caused by the isolation procedure since cells which were directly boiled in SDS prior to electrophoresis also contain substantial amounts of free β-galactosidase in addition to the intact fusion product.
Reaction of the expressed proteins with monoclonal antibodies specific for the 32 Kd host-protective antigen
A number of monoclonal antibodies (Mab)that recognise the 32 Kd structural protein of IBDV and/or neutralize the virus have been produced (see later) .
These fall into two classes. One class of Mabs (e.g.17-80) reacts with the 32 Kd proteins on Western blots but do not neutralize the virus, while the other class of Mabs (e.g.17-82) neutralize the virus but do not significantly react with the 32 Kd protein on Western blots. This suggests that the virus neutralizing monoclonal antibodies recognize a conformational epitope.
The fusion proteins expressed in clones Dl and D6 when boiled in SDS, react very strongly with monoclonal antibodies that recognize the 32 Kd structural proteins on Western blots. Both the expressed fusion proteins, when not treated with SDS, also react weakly but specifically with monoclonal antibodies that neutralize the virus. What is significant is that the IBDV polypeptide expressed in clone Dl is only 150 amino acid residues long and constitutes about half of the 32 Kd protein but contains the epitope that is recognized by the MAb that is specific for the 32 Kd protein on Western Blots (17-80) , and at least a part of the epitope recognised by the MAb that neutralizes the virus (17-82) .
Immunogenicity of the expressed proteins
Fusion proteins from clones Dl and D6 were injected into both SPF chickens and chickens previously sensitised with live IBDV as described under Materials and Methods. The specificity of the antibodies in the sera obtained from both groups of chickens was analysed by Western blotting of whole IBDV particles boiled in SDS prior to electrophoresis (Fig.9).
Previously sensitized chickens had antibodies to the 32 Kd, 37 Kd and 42 Kd structural polypeptides of IBDV at relatively low levels prior to vaccination with the fusion proteins. Fusion proteins from clones D6 and Dl recalled a specific anti-32 Kd antibody response in all these chickens, while the intensity of binding to the other structural proteins remained unchanged.
In unprimed SPF chickens the fusion proteins induced the synthesis of antibodies in only some of the chickens. When antibodies were detected, however, they were specific by Western blotting for the 32 Kd structural polypeptide of IBDV. Thus the fusion proteins expressed in clones D6 and Dl induce antibodies specific for the 32 Kd polypeptide in both primed and unprimed chickens.
The sera obtained from the sensitized and SPF chickens vaccinated with the fusion proteins were assessed by the ELISA and micro-virus neutralization assays which were designed to recognize the protective immunogen in its native conformation. The levels of antibody detectable by ELISA did not increase by more than 2-4 fold above pre-existing levels in sensitized chickens or above base-line levels (<1:100) in SPF chickens, even though they reacted very strongly with Western blotted viral proteins.
The virus neutralization assay also showed no dramatic increase in the levels of antibody in previously sensitized chickens, but detected a titre of 1:320 to 1:160 in one of two SPF chickens vaccinated with affinity purified protein from clone Dl. The antibody titre peaked 3 to 4 weeks after the second
injection of protein from clone Dl and persisted for more than 6 weeks. By Western blotting, the polyclonal response of this chicken to Dl protein was specific for the 32 Kd polypeptide of IBDV.
Thus the antibodies produced against the fusion proteins react very specifically and strongly with
Western blotted 32 Kd host-protective antigen of IBDV, but have relatively weak ELISA titres, and virus neutralization activity in only 1 out of 4 chickens. In addition, the expressed proteins react very weakly with monoclonal antibody that neutralizes the virus. These results strongly suggest that the expressed IBDV proteins fused to β-galactosidase, though immunogenic, do not have the right conformation necessary for the consistent induction of virus neutralizing or protective antibodies. The expression of unfused proteins with the right conformation will probably be required to produce a more effective subunit vaccine against IBDV.
In this context, it should be reiterated that the serum of one chicken, injected with fusion protein from clone Dl, had significant virus neutralization activity.
In this instance, the IBDV protein could have been proteolytically cleaved off the β-galactosidase and assumed the conformation required for inducing virus neutralizing antibody response. In subsequent experiments, unfused 32Kd protein has been produced by expressing the gene for the 32Kd protein in vectors that produce unfused proteins. This unfused protein reacted with the virus neutralizing MAb 17-82, though to a lesser extent than with MAb 17-80 that preferentially reacts with denatured 32Kd protein. Thus, one avenue for producing the 32Kd antigen with the correct
three-dimensional structure is to cleave off the IBDV antigen from affinity purified fusion protein by chemical or enzymatic cleavage at the junction of the two proteins. Although this method may require a further refolding step, the level of expression of fusion protein, in comparison to unfused protein, is very high and the fusion protein can be readily purified by affinity chromatograph .
The following detailed description relates to the determination of the nucleotide sequence of the large segment of IBDV RNA and the amino acid sequence of cDNA clones that encode the 32 Kd host-protective antigen of IBDV. In the accompanying diagrams:
Figure 10 shows sequence analysis of the large RNA segment of IBDV. The predicted amino acid sequence is presented in single letter code above the nucleotide sequence derived from cDNA clones. There are no other extensive open reading frames. The amino acid sequences are numbered sequentially from the N-terminus of the 37Kd protein as position 1. The region encompassed by cDNA clones M7, G6, L6, D6 and Dl are indicated. Dibasic residues are boxed and the repeat unit A-X-A-A-S is similarly highlighted. N-terminal sequences derived from tryptic peptides are shown overlined as (- - - ->) for the 37Kd, (....>) for 28Kd and ( >) for the 32Kd protein. Only the N-terminus of the 37Kd protein could be obtained by direct sequencing on intact proteins and this is shown from residue 1.
Results and Discussion Random nucleotide sequencing
A mixed population of cDNA inserts (350-2000 bp) spanning the entire large RNA segment of IBDV was recovered on DEAE-cellulose from a 1% agarose gel after Pst 1 digestion of the selected cDNA library. After purification on a NACS column (Schleicher & Schull) the homopolymeric tails were removed using Bal 31 exonuclease in a controlled reaction (2 units, 20°C, 10 minutes) designed to digest no more than 50 nucleotides from either end. The fragments were then blunt-ended with DNA polymerase (Klenow fragment) and ligated into a Sma I restricted M13mpl0 vector followed by transformation of E.coli JM101 (Sanger et.al. , 1980). Single-stranded templates were sequenced by the primed synthesis method using an M13-specific primer (Sanger et.al. , 1980) but with modificatons that improved transcription fidelity over regions of secondary structure in the template. These included removal of NaCl from the buffer, using reverse transcriptase and optimized ratios of dideox :deoxy nucleotides (1:30A; 2:15C; 1:15G; 2:3T) and performing the reaction at 30°C or greater. Sequences were compiled using a VAX/UMS computer system using the programmes of Staden (1982) with modifications by Dr. T. Kyne.
Directed chemical sequencing
Specific cDNA fragments in either pBR322 or pUR expression vectors were sequenced by the Maxam and Gilbert (1977) procedure after first identifying a restriction site which could be end labelled with reverse transcriptase and either α- 32P-dATP or - 32P-dCTP at 37°C for one hour. This method often
required a second restriction digest after the reverse transcriptase step to generate a molecule with a radiolabel at only one end. The fragments were then purified by electroelution from an 8% polyacrylami.de gel. After chemical degradation the sequencing samples were loaded on denaturing polyaerylamide gels (Sanger and Coulson, 1978) which contained 90% formamide. Under these conditions when 20 cm x 40 cm gels were run at 25W on an apparatus that maintained the temperature above 50°C the secondary structure was completely disrupted.
Nucleotide sequence analysis of the large RNA segment of IBDV
Since the cDNA library was constructed with G/C homopolymeric tails of average length 20-30 nucleotides we were unable to obtain clear sequences directly over these tails by the simple subcloning of PstI fragments into Ml3 ventors. Instead we.adopted the strategy of using Bal 31 exonuclease to remove the tails and then subclone random cDNA fragments of the IBDV genome b . blunt-end ligation into Sma I digested Ml3mpl0. The cDNA fragments were initially selected as having originated from the large RNA segment by colony hybridization with a specific probe. Random nucleotide sequences were rapidly sorted and overlapped into a consensus sequence with the aid of computer programmes. The final alignment comprised 2950 bp and was constructed from over 60 overlapping sequences . No point mutations or rearrangements were found in the overlapping sequences which confirms that the original library construction by randomly primed transcripts followed by reannealing and polymerase elongation was remarkably error-free.
However, two problems emerged with this approach. Firstly the subcloning was definitely not random; some regions were sequenced many times whereas cDNA fragments containing the region from nucleotides 2250-2600 could not be subcloned into M13. Secondly the general quality of nucleotide sequence obtained by the chain termination method of Sanger et.al. (1980) was poor due to multiple regions of secondary structure causing premature terminations in the transcriptase reaction. This latter problem was partly overcome by the use of reverse transcriptase under optimized conditions rather than the standard DNA polymerase (Klenow fragment) . These secondary structure problems appear to be particularly severe for this double stranded RNA virus since other genes being sequenced at the same time (Hudson et.al. , 1984; Mclntyre et.al. , 1985). To overcome these problems we resorted to the chemical degradation technique of Maxam and Gilbert (1977) which is less affected by secondary structure and the use of denaturing forma ide gels to resolve the sequencing ladder. Interestingly, the region with the most severe secondary structure problems (nucleotides 2540-2565) was contained within the fragment which could not be subcloned into M13. The significance of this structure which is lethal to M13 has not been further characterized; it is contained within the coding region of the 32Kd protein product.
Identification of the gene encoding the 32Kd host-protective immunogen
Two methods were attempted in parallel; protein sequencing of tryptic peptides derived from purified 32Kd protein and identification by immunoblot assay of cDNA clones expressing fragments of the 32Kd antigen as
a fusion protein. For the expression studies vectors have recently been described in which cDNA fragments can be ligated into the 3'end of the β-galactosidase gene (Ruther and Muller-Hill, 1983; Stanley and Luzio 1984).
5 The fusion proteins produced by these constructions appear to be particularly stable and has lead to claims of hybrid-protein synthesis up to 30% of the host cell proteins. With suitable inducible promoters sufficient protein is produced to form amorphous aggregates
10 appearing as inclusion bodies. Plasmid vectors which have been designed to express only the gene encoded by the cDNA (pUC, pCQV) do not appear to produce such high levels of expressed protein. For these reaons we chose to subclone a mixed population of cDNA fragments
15 spanning the entire IBDV genome, still containing homopolymeric tails, into the Pst I site of vectors pUR290, pUR291, pUR292 to ensure translation in all three reading frames. Recombinant colonies were >Α screened by an immunoblot assay using a monoclonal
20 antisera raised against denatured-32Kd protein (see later) followed either by autoradiography using
125 I-protein A or visible detection by a peroxidase conjugated second antisera. Two colonies expressed the epitope recognised by the anti-32 Kd antisera; one was a
25 direct subclone of the 1100 bp fragment D6 described previously, and the other a shorter 450 bp cDNA fragment
Dl entirely contained within D6 (Fig. 10) .
Directed nucleotide sequencing over the 30 homopolymeric tails from the EcoRI site in the pUR vector readily identified both the cloning vector (pUR290 for Dl; pUR291 for D6 and the translation phase of the recombinant product. The entire nucleotide sequence of D6 and Dl was obtained by the Maxam and
35
Gilbert technique on suitable end-labelled fragments. This sequence overlapped the consensus generated by the random sequencing approach, thus spanning the region which could not be subcloned into Ml3 and completing the 3129 bp genome presented in Fig. 10.
With the exception of the D6 region the rest of the genomic sequence had been compiled from multiple independent cDNA clones. Although this random approach showed that the original construction of the cDNA library was remarkably error-free we were concerned that regions with secondary structure in D6 could have been transcribed incorrectly. To settle this point two further clones (G2 and Nl) spanning residues 1250-2750 and 2210-3150 respectively were sequenced completely by the direct chemical method. No ambiguities were found between D6 and these clones indicating that the transcription of the IBDV genome was correct. The only differences observed between any cDNA clones were always located in the last ten nucleotides adjacent to the homopolymeric tails. These sequences are known to contain potential errors generated by the DNA polymerase fill-in reaction (Hudson et.al. , 1984) and were therefore not included in the consensus. Any areas of potential ambiguity due to secondary structure affecting the random sequencing approach were resolved by direct chemical sequencing from a suitable restriction site within the cDNA inserts of M7, A3, L6, G2 or D6 which together span the entire sequence presented in Fig. 10.
The 5' and 3' terminal sequences of the consensus are defined by the ends of M7 and D6 respectively.
Structure of the 32Kd antigen
On Fig. 10 arrows indicate the translational phase in the pUR subclones of D6 and Dl bearing in mind that the initial residue adjacent to the homopolymeric tails has not been included. Although the termination codon at residue 3065 is unambiguous, the N-terminal residue of the 32K antigen is not clear. If the protein is generated from a polycistronic RNA template as implicated for the related IPNV or Drosphila X viruses we would expect initiation at MET 2287 giving rise to a product of 29Kd which is consistent from size estimates. However if the 32Kd protein is generated by processing of a precursor we might expect proteolytic cleavage somewhere before the MET residues, assuming the C-terminus is intact.
Peptide sequencing of tryptic fragments has confirmed both the reading phase predicted from the D6 and Dl expression vectors and that the 32Kd protein spans residues 2372-3008. All nine peptides sequenced to date are located from the region 3' to MET 2287. However, the intact 32Kd antigen has a blocked N-terminus which perhaps suggests Gin 2274 as the N-terminal residue after proteolysis.
The amino acid sequence derived from the complete nucleotide sequence of the large segment of the IBDV genome is shown in Fig.10. Partial peptide sequencing of purified viral proteins has confirmed these sequences and allowed the positioning of the coding regions of the viral proteins on the large segment of the genome. There is only one translation termination codon at the 3' end of the genomic RNA, and it would appear that the
entire genome is expressed as a single polyprotein in which the viral proteins are arranged in the following order: N- 41/37Kd - 28Kd - 32Kd - C. The exact processing mechanism of this large precursor to the
5 viral proteins has not yet been defined. Dibasic residues, which are frequent targets for eukaryotic precursor proteins, are conveniently situated at residues 451-452 and 721-722 and cleavage at these sites would excise a predicted 28.2Kd protein. The cleavage
10 sites are consistent with peptide sequencing data which confirms that the 37Kd protein spans at least base residues 32-1310, the 28Kd protein at least base residues 1660-1870, and the 32Kd protein at least base residues 2310-3030. The region encoding the 37Kd
15 protein is also expected to encode the larger 52Kd and 41Kd precursors of the 37Kd protein. An alternative cleavage site could be the peptide sequence A-X-A-A-S which is repeated three 'times between residues 483-503 r- and also appears at residues 752-756.
20
The following detailed description relates to the production of monoclonal antibodies (MAbs) to IBDV and to the identification of a neutralising epitope on IBDV using these monoclonal antibodies. In the accompanying
25 diagrams:
Figure 11 shows Western blot analysis of anti-IBDV
MAbs against whole virus following SDS-PAGE.
Figure 12 shows competitive ELISA between anti-IBDV MAbs and a chicken anti-32Kd specific antisera
30 to IBDV.
Results and Discussion
Mouse monoclonal antibodies (MAbs) to IBD virus were prepared by hyper-immunising Balb/C mice with
35
purified virus and fusing the immune spleen cells with SP2/0 myeloma cells according to the method of Hewish et.al (1984) . Antibody secreting colonies were detected by an Immunodot assay (Bio Rad) on whole virus and by the IBD virus ELISA described in International Patent Specification No. PCT/AU84/00256, modified to detect mouse antibodies by using goat anti-mouse Ig-HRP (Bio Rad) . The positive colonies were cloned by limiting dilution on at least 3 occasions, selecting positive colonies by the above assays at each cloning.
The specificity of the MAbs was assessed by Western blotting whole virus (Patent Specification No. PCT/AU84/00256) again modified to detect mouse antibodies by using rabbit anti-mouse Ig (Sera-lab) . The majority of MAbs were specific for the 32Kd structural polypeptides of IBD virus, as exemplified by the series 1 and 17 MAbs shown in Fig. 11. Only one series of MAbs, series 6, recognised the 42Kd polypeptide (Fig. 11) and none have yet been obtained that specifically react with the 37Kd polypeptide. A subclone of the series 17 MAbs, designated 17-82, did not bind to SDS denatured IBD viral polypeptides (Fig. 11) . All the MAbs that were positive for viral polypeptides on Western blots also bound to material on the blots that were of lower mol. wt. than any of the known structural proteins of IBD virus (Dobos, 1979; Patent Specification No. PCT/AU84/00256) and may therefore represent degraded viral proteins. The anti-32Kd moloclones, particularly of the 17-80 and 17-83 lineage bound to a large molecule which had an approximate mol. wt. of 55Kd and may represent the unprocessed precursor molecule described earlier.
The relative antibody activity of the MAbs was assessed by the ELISA and the Immunodot assay; the latter on both denatured and nondenatured virus (Table 1) . Ascites fluid from mice inoculated with myeloma cells of the series 1 and 17 all had high titres of antibodies by the ELISA and Immunodot assays (2 14219) performed on native virus, although the Immunodot reactivity of the 17-82 lines was abolished by treatment of the virus with SDS and boiling. The series 6 MAbs reacted weakly in both assays (Table 1) , although this time the reactivity of the MAbs in the Immunodot assay was enhanced by treating the virus with SDS and boiling.
TABLE 1 Summary of the specificity, relative activity and isotypes of the MAbs to IBD virus.
AB Specificity
AB Activity
MAb AB
Western Competi- - -_iτ.__τ.LoσAι. Immunodot Virus Iso- blot ive ELISA -SDS +SDS Neutral- type isation
1 32Kd ? ++++ +++ +++ - G^^
6 42Kd ? + + +++ - G.,
17-80 32Kd ? +++ +++ ++++ - G1
17-82 ? 32Kd ++++ ++++ - ++++ G ,
When the virus neutralizing activity of the MAbs was assessed in the micro-virus neutralization assay
(Patent Specification No. PCT/AU84/00256) only the MAbs of the 17-82 lineage neutralized the infectivity of the virus; the ascites fluid having a titre of 2 . MAbs of the series 1 and 6 and of the 17-80 lineage were all
4 negative (<2 ) .
The specificity of the 17-82 MAbs was investigated in a competitive inhibition ELISA against chicken antisera specific for the 32Kd polypeptide of IBD virus by Western blotting. The 17-82 MAbs effectively competed out the chicken anti-32Kd antibodies (Fig. 12) , while the 17-80 and series 6 MAbs were much less effective (Fig. 12) . The 17-82 MAbs also completed out a polyspeσific chicken antisera, which recognized the 32Kd, 37Kd and 42Kd viral polypeptides on Western blots (data not shown) , indicating that the 17-82 MAbs were against a dominant immunogen on the virus.
The isotype of the anti-IBD virus MAbs was determined by an ELISA utilising either anti-mouse lambda chain, IgM, IgGl, IgG2a+2b, IgG2b or IgG3 as the second step reagent. All MAbs were of the mouse IgGl class except the 17-82 line MAbs, which were of the IgG2b class.
The series 6 MAbs were of particular interest as we believe from HPLC analysis of a tryptic and chrymotryptic digest of the 37Kd and 42Kd polypeptides that the latter is the precursor of the former. It would seem likely therefore that the series 6 MAbs recognise the peptide sequence cleaved off during the
formation of the major 37Kd structural polypeptide of the Australian type-1 IBD virus.
Because of their ability to recognise SDS denatured 32Kd polypeptide of IBD virus, MAbs of the 17-80 lineage were used to select recombinant bacterial colonies expressing part or all of the 32Kd polypeptides as described above.
The following detailed description relates to the production of the 32Kd structural protein in its unfused form. In the accompanying diagrams:
Figure 13 shows proteins expressed in clones D6, Dl and PI, and IBDV proteins, which were Western blotted and reacted with MAb 17-80. The insert of clone PI was constructed by ligating the L6 and D6 inserts via the Apa I restriction site to retain the exact genomic sequence of native IBDV over this region.
Figure 14 shows clones Dl, D6 and Pi which were lysed by various treatments and the proteins blotted onto nitrocellulose filters, then reacted with either
MAb 17-80 or MAb 17-82. The expressed proteins were visualised by reaction with [ 125I] Protein A followed by autoradiography. Figure 15 indicates the minimum size of precursor polypeptide that has to be expressed for the correct processing of the 32Kd antigen. The insert of clone PO, that contains the entire coding region of the large segment of IBDV genome, was progressively shortened at the 5' end at specific restriction sites and the resultant fragments were expressed in pPL vector in E.coli. Expressed gene products were Western blotted and reacted with MAb 17-80.
Figure 16 indicates the regions of the precursor polypeptide that may contribute to the antigenic determinant recognised by the virus neutralising monoclonal MAb 17-82. Undenatured proteins from clones containing precursors of varying sizes were blotted onto nitrocellulose filter and reacted with MAb 17-80 or MAb 17-82.
A large recombinant molecule spanning bases 425-3145 was constructed by joining the inserts of clone D6 (which encodes the 32Kd protein) and clone L6 (which encodes the 28Kd protein and the major part of the 41/37Kd protein) - full details of both these clones are set out above. L6 and D6 inserts were ligated via the Apa I restriction site to retain the exact genomic sequence of native IBDV over this region. This large recombinant molecule (PI) was expressed in pUR plasmids in E.coli and the expressed protein analysed by Western blotting and reaction with MAb 17-80 (Fig.13). The large insert was expected to express a viral polyprotein of M>80Kd (or ^ 190Kd as a fusion protein) but instead produced a discrete 32Kd protein that specifically reacted with MAb 17-80.
To see if the correct processing of the expressed polypeptides leads to their being correctly folded the proteins expressed in clone PI were analysed by an immunoblot assay (Fig.14) using a monoclonal antibody (Mab 17-82) that neutralises the virus but does not react with denatured 32Kd viral protein. The expressed proteins reacted quite strongly with MAb 17-82, but this reaction was completely abolished when the expressed protein is first denatured in SDS. After denaturation in SDS, the expressed protein reacted
strongly with MAb 17-80 which recognises denatured 32Kd protein. Thus, the genetically engineered polypeptides mimic the immune response of the whole virus particle towards MAb 17-82 and MAb 17-80.
These results clearly demonstrate that the expression of a large cDNA fragment encoding the 32Kd protein, the 28Kd protein and a major portion of the 41/37Kd protein results in the synthesis of an unfused 32Kd protein that is recognised by a monoclonal antibody (Mab 17-80) which reacts with denatured 32Kd host-protective antigens of IBDV. In the "native" form, the genetically engineered polypeptides react specifically with the virus neutralising monoclonal antibody (Mab 17-82) suggesting that they may be folded in the same conformation as the native viral antigen.
A larger recombinant molecule (P0) containing the entire coding region of the large RNA segment of IBDV was constructed by ligating the insert of clone PI to the insert of another clone G6 through a common Ndel restriction site. P0 was expressed in pEX vector (Stanley and Luzio, (1984)), in E.coli. As in the case of Pi, this resulted in the production of a correctly processed 32Kd polypeptide that reacted with MAb 17-80.
The 32Kd protein produced in clones PI and P0 might be processed by a virus-specified protease. Alternatively, a translation initiation site recognised by E.coli ribosomes may be present within or just before the gene for the 32Kd protein. If this is the case then the introduction of frame shifts within the 28Kd protein should not affect the production of the 32Kd polypeptide
in clone P0. Frame shifts were introduced by inserting the 1.3Kb Km fragment (Vieira and Messing (1982)) into the EcoRl or Bam HI sites within the gene for the 28Kd protein, or by deleting the EcoRl - Bam Hi fragment. In none of these instances was a 32Kd or higher MW protein produced that reacted with MAb 17-80 on Western blots. This ruled out the possibility that the 32Kd protein is expressed from an independent translation initiation site.
In order to localize the putative virus-specified protease the insert from clone P0 was progressively shortened from the 5' end at specific restriction sites (Fig.15) and resultant fragments of different sizes were inserted into vectors that produced either fusion proteins or unfused proteins, and the same results were obtained irrespective of the type of vector used. The proteins expressed in E.coli were Western blotted and reacted with MAb 17-80 (Fig.15) to see how much of the coding sequence besides the 32Kd polypeptide has to be expressed in order to produce the correctly processed 32Kd protein. Fig.15 shows the results obtained by expression in a fusion vector (pPL) that adds on about 7Kd of the XN gene product to the expressed protein.
The deletion of part or whole of the gene coding for the 52Kd precursor of the 37Kd protein or the N-terminal portion of the 28Kd protein did not in any way interfere with the production of the 32Kd polypeptide. However, the removal of further portions of the gene encoding the 28Kd protein (Bam HI and Hind III restriction sites) inhibited the processing of the 32Kd protein even though the dibasic residues at the
approximate junction between the 32Kd and 28Kd proteins were still present. Similar results were obtained by site-specific insertional mutagenesis studies using Km cassettes (Vieria and Messing, (1982)). Insertion of 10 codons 'in-phase' into the EcoRl site near the 5' end of the 28Kd protein does not affect the production of the correctly processed 32Kd protein, whereas the insertion 'in-phase' of 4 codons into the Bam HI site in the middle of the 28Kd protein inhibits the processing of the 32Kd protein and a much large precursor molecule is produced.
These results together with the fact that the 28Kd protein is present in very minute and variable quantities in the mature virus particle would suggest that the 28Kd protein is an IBDV specific protease involved in the processing of the large precursor polypeptide.
The proteins expressed in clones Pi and P0 react strongly with the virus neutralizing MAb 17-82. Since clones PI and P0 produce correctly processed 32Kd protein and other proteins encoded by the large segment it was important to know whether the correct processing of the proteins resulting from the expression of large precursor molecules leads to the expressed polypeptides assuming the correct 3-dimensional structure that is recognised by the virus neutralizing MAb 17-82. Recombinant molecules of various sizes containing the gene for the 32Kd protein and part or whole of the gene(s) for the 28Kd and 52Kd proteins, were expressed in E.coli. The undenatured expressed proteins were blotted onto nitrocellulose filter and reacted with MAb 17-80 or MAb 17-82 (Fig.16). While MAb 17-80 reacted
46 of epitope(s) that induce virus neutralising and/or protective antibody.
Thus one viable approach to producing the correctly processed and folded antigens is to express the entire coding region or precursors retaining the 32Kd, 28Kd and a substantial portion of the 52Kd precursor proteins. The antigens produced by this method can be readily purified by affinity chromatography using monoclonal antibodies, or by engineering specific sequences at the termini of the expressed antigens.
Another approach is to express the complete gene or fragments thereof for the 32Kd and/or the 52Kd protein. A ubsequent refolding step may or may not be required. This approach is quite feasible since we have previously demonstrated (International Patent Application PCT/AU84/00256) that the viral 32Kd protein isolated from SDS-polyacrylamide gel can refold and when injected into chickens produce virus neutralizing and protective antibodies. Moreover, an unfused protein of 30Kd produced by the expression of the Ahall - Pst 1 fragment of the 32Kd gene in pCAV2 vector reacts with the virus neutralizing MAb 17-82. The protein expressed from the gene for the 52Kd precursor of the 41Kd and 37Kd structural proteins also reacts with the virus neutralising MAb 17-82.
third approach to producing the viral antigen in E.coli is to produce fusion proteins in which an enzymic or chemical cleavage site has been engineered at the junction between the IBDV and host proteins. The levels of expression of fusion proteins are very high
45 with proteins expressed in all the constructs, the virus neutralizing MAb 17-82 only reacted with proteins expressed in clones in which the substantial portion of the 52Kd precursor of the 37Kd protein is retained (Fig.16). On the'other hand. Fig.15 clearly shows that the correct processing of the 32Kd protein does not require any portion of the 52Kd protein or even the extreme N-terminal portion of the 28Kd protein. Thus the correct processing of the 32Kd protein alone does not ensure recognition by MAb 17-82, and a portion of the 52Kd precursor protein may be directly or indirectly involved in the process.
The antigenic determinant recognised by the virus neutralizing MAb 17-82 may consist of a discontinuous epitope made up of contributing regions from both the 32Kd and 41/37Kd proteins. Fusion proteins from clones D6 and Dl in the undenatured state, react weakly, but quite specifically with virus neutralising MAb 17-82. Unfused protein produced by the expression of the Aha II - Pst 1 fragment of the 32Kd gene, also react with MAb 17-82. Thus the 32Kd protein or part thereof, is recognised albeit weakly by MAb 17-82. In order to see if MAb 17-82 also reacted with the 52Kd precursor protein of the 41 and 37Kd structural proteins, the gene encoding this region, without those genes coding for the 28Kd and 32Kd structural proteins, was expressed in pEX vector in E.coli. The undenatured expressed protein reacted strongly with MAb 17-82, indicating that the 52Kd precursor also contained an epitope(s) recognised by the virus neutralising MAb. It is possible that an interaction between the 32Kd and the 41/37Kd structural proteins may be involved in formation
and the expressed protein can be readily purified by affinity chromatograph . The IBDV protein can be recovered by enzymic or chemical cleavage of the purified fusion protein.
REFERENCES
1. BIRNBOIM, H.D.,_and DOLY, J. (1979) Nucl. Acids Res. 7, 1513-1523.
2. BLAKE, A. and PEACOCKE, A.R. (1968). Biopolymers 6, 1225-1253.
3. DIAZ-RUIZ, J.R., and KAPER-, J.M. (1978). Prep. Biochem. 8, 1-17.
4. DOBOS, P. (1979). J. Virology, 32, 1046-1050."
5. FIRTH, G.A., (1974). Aust. Vet. J. 50, 128-130.
6. GOLDBACH, R. . , BORST, P., BOLLEN-DE BOER, J.E. , and VAN BRUGGEN, E.F.J. (1978). Biochem, Biophys. Acta 521, 169-186.
7. GRUNSTEIN, M. and HOGNESS, D.S. (1975). Proc. Natl. Acad. Sci. USA 72, 3961-3965.
8. HEWISH, D.R., ROBINSON, C.P. and SPARROW, L.G. (1984). Aust.J.Biol.Sci., 3_7, 17-23.
9. HUDSON, P., JOHN, M. , CRAWFORD, R. , HARALAMBIDIS, J., SCANLON, D., GORMAN, J. , TREGEAR, G. , SHINE, J., and NIALL, H. (1984) EMBO J. 3_, 2333-2339.
10. ISH-HOROWICZ, D., and BURKE, J.F. (1981). Nucl. Acids Res. 9, 2989-2998.
11. LERMAN, L.S. (1963). Proc. Natl. Acad. Sci. USA 49, 94-102.
12. MARGLIN, A., and MERRIFIELD, R.B. (1970) Auno. Rev, Biochem., 3_9, 841»
13. MAXAM, A.M. and GILBERT, W. (1977) Proc. Natl. Acad. Sci. 7_4, 5463-5467.
14. McINTYRE, P., GRAF, L., MERCER, J. , WAKE, S., HUDSON, P. and HOOGENRAAD, N. (1985) DNA 4_, in press.
15. MULLER, H. , SCHOLTISSEK, C. and BECHT, H. (1979). J. Virol. 31, 584-589.
16. RIGBY, P.W.J., DIECKMANN, M. , RHODES, C. , and BERG, P. (1977). J. Mol. Biol. 113, 237-251.
17. RIXON, F., TAYLOR, P., and DESSELBERGER, U. (1984). J. Gen. Virol. 65, 233-239.
18. RUTHER, ϋ. and MULLER-HILL, B. (1983) EMBO J. 2 , 1791-1794.
19. SANGER, F. , COULSON, A.R. , BARRELL, B.G., SMITH, A.J.H. and ROE, B.A. (1980) J. Molec. Biol. 143, 161-178.
20. SANGER, F. and COULSON, A.R. (1978) FEBS Lett. 81_r 107-110.
21. STADEN, R. Nucleic Acids Res. (1982) 3 , 4731-4751.
22. STANLEY, K.K. and LUZIO, J.P. (1984) EMBO J. 3_, 1429-1434.
23. TAYLOR, J.M., ILLMENSEE, R. , and SUMMERS, J.
(1976). Biochem. Biophys. Acta 442, 324-330.
24. TODD, D., and McNULTY, M.S. (1979). Arch. Virol. 60, 265-277.
25. ULLMANN, A." (1984). Gene. 29_, 27-31.
26. VIEIRA, J., and MESSING, J. (1982). Gene. 1^9, 259-268.
Claims
1. A recombinant DNA molecule comprising a nucleotide sequence substantially corresponding to all or a portion of IBDV RNA.
2. A DNA molecule according to claim 1, wherein said nucleotide sequence substantially corresponds to all or a portion of the IBDV RNA segment of approximately 3400 b.p.
3. A DNA molecule according to claim 1, wherein said nucleotide sequence codes for all or a part of at least one structural protein of IBDV.
4. A DNA molecule according to claim 3, wherein said nucleotide sequence codes for all or part of the 32Kd structural protein of IBDV, or a polypeptide displaying antigenicity which substantially corresponds to the 32Kd structural protein of IBDV.
5. A DNA molecule according to claim 4, wherein said nucleotide sequence codes for all or part of the 32Kd structural protein of IBDV, or a polypeptide displaying the antigenicity thereof, in the form of a fusion protein.
6. A DNA molecule according to claim 4, wherein said nucleotide sequence codes for all or part of the 32Kd structural protein of IBDV, or a polypeptide displaying the antigenicity thereof, together with further portion(s) of the 3400 b.p. segment coding for further polypeptides or proteins to correctly process said 32Kd .structural protein. 51
7. A DNA molecule according to claim 3, wherein said nucleotide sequence codes for all or part of the 52Kd precursor protein of IBDV, or a polypeptide displaying antigenicity which substantially corresponds to the 41/47Kd structural protein of IBDV.
8. A DNA molecule according to claim 7, wherein said nucleotide sequence codes for all or part of the 52Kd precursor protein of IBDV, or a polypeptide displaying antigenicity of the 41/37Kd structural protein, in the form of a fusion protein.
9. A DNA molecule according to claim 7, wherein said nucleotide sequence codes for all or part of the 52Kd precursor protein of IBDV, or a polypeptide displaying antigenicity of the 41/37Kd structural protein, together with further portion(s) of the 3400 b.p. segment coding for further polypeptides or proteins to correctly process said 41/37Kd structural protein.
10. A DNA molecule according to claim 1, wherein said nucleotide sequence is characterised by at least a portion thereof comprising a base sequence substantially as shown in Figure 10, or one or more portions of said base sequence.
11. A recombinant DNA molecule comprising a nucleotide sequence capable of being expressed as all or a part of at least one structural protein of IBDV, or a polypeptide displaying the antigenicity thereof.
12. A recombinant DNA molecule comprising a nucleotide sequence according to any one of claims 1 to 11, operatively linked to an expression control sequence.
13. A recombinant DNA cloning vehicle or vector capable of expressing ll or a part of at least one structural protein of IBDV, or a polypeptide displaying the antigenicity thereof, and having inserted therein a nucleotide sequence according to any one of claims 1 to 11, said sequence being operatively linked to an expression control sequence.
14. A host cell containing a recombinant DNA molecule according to claim 12, or a recombinant DNA cloning vehicle or vector according to claim 13.
15. A synthetic peptide or polypeptide displaying the antigenicity of all or a part of at least one structural protein of IBDV.
16. A synthetic peptide or polypeptide according to claim 15, characterised in that it displays the antigenicity of the 32Kd structural protein of IBDV.
17. A synthetic peptide or polypeptide according to claim 15, characterised in that it displays the antigenicity of the 41/37Kd structural protein of IBDV.
18. A synthetic peptide or polypeptide according to claim 15, characterised in that it displays the antigenicity of the 32Kd structural protein of IBDV in its correctly processed form, substantially free of any foreign polypeptide or protein.
19. A synthetic peptide or polypeptide according to claim 15, characterised in that it displays the antigenicity of the 41/37Kd structural protein of IBDV in its correctly processed form, substantially free of any foreign polypeptide or protein.
20. A fused polypeptide comprising a polypeptide sequence displaying the antigenicity of all or a part of at least one structural protein of IBDV, as jthe C-terminal sequence, and an additional polypeptide as the N-termimal sequence fused thereto.
21. A fused polypeptide according to claim 20, wherein said polypeptide sequence displays the antigenicity of the 32Kd structural protein of IBDV.
22. A fused polypeptide according to claim 20, wherein said polypeptide sequence displays the antigenicity of the 41/37Kd structural protein of IBDV.
23. A fused polypeptide according to claim 20, wherein the additional polypeptide is a polypeptide coded for by the DNA of a recombinant DNA cloning vehicle or vector.
24. A method of preparing a synthetic peptide or polypeptide according to any one of claims 15 to 19, or a fused polypeptide according to any one of claims 20 to 23, which comprises expression of a host cell according to claim 14, and recovery of the synthetic peptide or polypeptide or fused polypeptide.
25. A monoclonal antibody characterised in that it recognises the structural proteins of IBDV which are involved in neutralisation of the virus.
26. A monoclonal antibody according to claim 25, characterised in that it recognises the 32Kd structural protein of IBDV.
27. A composition for stimulating an immune response against IBDV, which comprises at least one synthetic peptide or polypeptide displaying the antigenicity of all or a part of at least one structural protein of IBDV, together with a pharmaceutically acceptable carrier therefor.
28. A composition according to claim 27, which comprises a synthetic peptide or polypeptide according to any one of claims 15 to 19, or a fused polypeptide according to any one of claims 20 to 23.
29. A composition according to claim 27 or claim 28, further comprising an adjuvant.
30. A method of stimulating an immune response against IBDV in poultry, which comprises administering a composition according to any one of claims 27 to 29 to said poultry.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP86903153A EP0222842B1 (en) | 1985-05-30 | 1986-05-30 | Cloning and expression of host-protective immunogens of ibdv |
DE3650319T DE3650319T2 (en) | 1985-05-30 | 1986-05-30 | CLONING AND EXPRESSION OF ECONOMICAL IMMUNOGENS OF INFECTIOUS BURSAVIRUS (IBDV). |
DE2003199004 DE10399004I2 (en) | 1985-05-30 | 1986-05-30 | Cloning and expression of host-protective immunogenic Bursavirus virus (ibdv). |
NL300114C NL300114I2 (en) | 1985-05-30 | 2003-01-30 | Cloning and expression of IBDV host-protecting immunogen. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPH0815/85 | 1985-05-30 | ||
AUPH081585 | 1985-05-30 | ||
AUPH211885 | 1985-08-23 | ||
AUPH2118/85 | 1985-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1986007060A1 true WO1986007060A1 (en) | 1986-12-04 |
Family
ID=25642952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1986/000156 WO1986007060A1 (en) | 1985-05-30 | 1986-05-30 | Cloning and expression of host-protective immunogens of ibdv |
Country Status (7)
Country | Link |
---|---|
US (2) | US6054126A (en) |
EP (1) | EP0222842B1 (en) |
JP (1) | JP2988622B2 (en) |
CA (1) | CA1334941C (en) |
DE (2) | DE3650319T2 (en) |
NL (1) | NL300114I2 (en) |
WO (1) | WO1986007060A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0481072A1 (en) * | 1990-05-04 | 1992-04-22 | University Of Maryland At College Park | Specific dna sequences related to an ibdv protein including vectors, hosts and vaccines |
US5254463A (en) * | 1981-09-18 | 1993-10-19 | Genentech, Inc. | Method for expression of bovine growth hormone |
US5350575A (en) * | 1987-06-26 | 1994-09-27 | Commonwealth Scientific And Industrial Research Organization | IBDV VP2 epitope recognized by virus neutralizing and protective monoclonal antibodies |
US5489529A (en) * | 1984-07-19 | 1996-02-06 | De Boer; Herman A. | DNA for expression of bovine growth hormone |
US5614409A (en) * | 1989-05-30 | 1997-03-25 | Commonwealth Scientific And Industrial Research Organisation | Production of IBDV VP2 in highly immunogenic form |
US5632989A (en) * | 1989-10-18 | 1997-05-27 | University Of Maryland | Attenuated, live vaccine for Delaware strain IBDV |
US5871744A (en) * | 1996-09-05 | 1999-02-16 | University Of Maryland-Biotechnology Inst. | Method for generating birnavirus from synthetic RNA transcripts |
WO2000012677A2 (en) * | 1998-09-01 | 2000-03-09 | The University Of Hong Kong | Generation of recombinant infectious bursal disease viruses by reverse genetics technology and the use of the recombinant viruses as attenuated vaccines |
US6231868B1 (en) | 1997-09-30 | 2001-05-15 | University Of Maryland-Biotechnology Institute | Method for generating nonpathogenic infections birnavirus from synthetic RNA transcripts |
WO2002088339A2 (en) * | 2001-05-02 | 2002-11-07 | Institut National De La Recherche Agronomique (Inra) | Bursal disease virus-like particles |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6165793A (en) * | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
WO2001097839A1 (en) * | 2000-06-19 | 2001-12-27 | Rahan Meristem | Recombinant vaccines against infectious bursal disease virus |
US6764684B2 (en) | 2001-09-28 | 2004-07-20 | Zeon Corporation | Avian herpesvirus-based recombinant infectious bursal disease vaccine |
US20040146530A1 (en) * | 2002-01-30 | 2004-07-29 | Sharma Jagdev M | Avian vaccine effective against infectious bursal disease virus |
ES2417019T3 (en) | 2003-11-13 | 2013-08-05 | University Of Georgia Research Foundation, Inc. | Characterization procedure of infectious bursitis disease virus |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4237224A (en) * | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
US4356270A (en) * | 1977-11-08 | 1982-10-26 | Genentech, Inc. | Recombinant DNA cloning vehicle |
EP0198828A4 (en) * | 1983-12-13 | 1986-11-04 | Commw Scient Ind Res Org | Infectious bursal disease virus vaccine. |
WO1988010298A1 (en) * | 1987-06-26 | 1988-12-29 | Commonwealth Scientific And Industrial Research Or | Ibdv vp2 epitope recognised by virus neutralising and protective monoclonal antibodies |
US5614409A (en) * | 1989-05-30 | 1997-03-25 | Commonwealth Scientific And Industrial Research Organisation | Production of IBDV VP2 in highly immunogenic form |
-
1986
- 1986-05-30 CA CA000510387A patent/CA1334941C/en not_active Expired - Lifetime
- 1986-05-30 EP EP86903153A patent/EP0222842B1/en not_active Expired - Lifetime
- 1986-05-30 DE DE3650319T patent/DE3650319T2/en not_active Expired - Lifetime
- 1986-05-30 DE DE2003199004 patent/DE10399004I2/en active Active
- 1986-05-30 WO PCT/AU1986/000156 patent/WO1986007060A1/en active IP Right Grant
-
1992
- 1992-06-23 US US07/902,846 patent/US6054126A/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/481,140 patent/US5849575A/en not_active Expired - Lifetime
-
1997
- 1997-01-16 JP JP9017817A patent/JP2988622B2/en not_active Expired - Lifetime
-
2003
- 2003-01-30 NL NL300114C patent/NL300114I2/en unknown
Non-Patent Citations (6)
Title |
---|
Journal of General Virology, Volume 66, No. 12, issued 1985 December (Colchester, Great Britain), K. FAHEY et al, "Antibody to the 32K Structural Protein of Infectious Bursal Disease Virus Neutralizes Viral Infectivity in Vitro and Confers Protection on Young Chickens", see pages 2693 to 2702. * |
Journal of General Virology, Volume 66, No. 7, issued 1985 July (Colchester, Great Britain), K. FAHEY et al, "Characterization by Western Blotting of the Immunogens of Infectious Bursal Disease Virus", see pages 1479 to 1488. * |
Journal of Virology, Volume 44, No. 1, issued 1982 October (Washington D.C., U.S.A.), H. MULLER et al, "Biosynthesis of Virus-Specific Proteins in Cells Infected with Infectious Bursal Disease Virus and their Significance as Strutural Elements for Infectious Virus and Incomplete Particles", see pages 384 to 392. * |
See also references of EP0222842A4 * |
Virology, Volume 143, No. 1, issued 1985 (New York, U.S.A.), A. AZAD et al, "The Characterization and Molecular Cloning of the Double-Stranded RNA Genome of an Australian Strain of Infectious Bursal Disease Virus", see pages 35 to 44. * |
Virology, Volume 149, No.2, issued 1986 March (New York U.S.A.), A. AZAD et al, Expression in Escherichia Coli of cDNA Fragments Encoding the Gene for the Host Protective Antigen of Infectious Bursal Disease Virus", see pages 190 to 198. * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5254463A (en) * | 1981-09-18 | 1993-10-19 | Genentech, Inc. | Method for expression of bovine growth hormone |
US5260201A (en) * | 1981-09-18 | 1993-11-09 | Genentech, Inc. | Methods and products for facile microbial expression of DNA sequences |
US5489529A (en) * | 1984-07-19 | 1996-02-06 | De Boer; Herman A. | DNA for expression of bovine growth hormone |
US5350575A (en) * | 1987-06-26 | 1994-09-27 | Commonwealth Scientific And Industrial Research Organization | IBDV VP2 epitope recognized by virus neutralizing and protective monoclonal antibodies |
US5614409A (en) * | 1989-05-30 | 1997-03-25 | Commonwealth Scientific And Industrial Research Organisation | Production of IBDV VP2 in highly immunogenic form |
US5632989A (en) * | 1989-10-18 | 1997-05-27 | University Of Maryland | Attenuated, live vaccine for Delaware strain IBDV |
EP0481072A4 (en) * | 1990-05-04 | 1993-06-09 | University Of Maryland At College Park | Specific dna sequences related to an ibdv protein including vectors, hosts and vaccines |
EP0481072A1 (en) * | 1990-05-04 | 1992-04-22 | University Of Maryland At College Park | Specific dna sequences related to an ibdv protein including vectors, hosts and vaccines |
US5871744A (en) * | 1996-09-05 | 1999-02-16 | University Of Maryland-Biotechnology Inst. | Method for generating birnavirus from synthetic RNA transcripts |
US6231868B1 (en) | 1997-09-30 | 2001-05-15 | University Of Maryland-Biotechnology Institute | Method for generating nonpathogenic infections birnavirus from synthetic RNA transcripts |
WO2000012677A2 (en) * | 1998-09-01 | 2000-03-09 | The University Of Hong Kong | Generation of recombinant infectious bursal disease viruses by reverse genetics technology and the use of the recombinant viruses as attenuated vaccines |
WO2000012677A3 (en) * | 1998-09-01 | 2000-06-29 | Univ Hong Kong | Generation of recombinant infectious bursal disease viruses by reverse genetics technology and the use of the recombinant viruses as attenuated vaccines |
WO2002088339A2 (en) * | 2001-05-02 | 2002-11-07 | Institut National De La Recherche Agronomique (Inra) | Bursal disease virus-like particles |
FR2824327A1 (en) * | 2001-05-02 | 2002-11-08 | Agronomique Inst Nat Rech | PSEUDOVIRAL PARTICLES OF BIRNAVIRUS |
WO2002088339A3 (en) * | 2001-05-02 | 2004-01-22 | Agronomique Inst Nat Rech | Bursal disease virus-like particles |
Also Published As
Publication number | Publication date |
---|---|
EP0222842A1 (en) | 1987-05-27 |
DE3650319D1 (en) | 1995-06-14 |
NL300114I2 (en) | 2003-10-01 |
JPH09316094A (en) | 1997-12-09 |
EP0222842A4 (en) | 1988-10-05 |
DE10399004I1 (en) | 2003-06-05 |
JP2988622B2 (en) | 1999-12-13 |
EP0222842B1 (en) | 1995-05-10 |
CA1334941C (en) | 1995-03-28 |
DE3650319T2 (en) | 1996-01-25 |
DE10399004I2 (en) | 2005-09-08 |
US6054126A (en) | 2000-04-25 |
NL300114I1 (en) | 2003-04-01 |
US5849575A (en) | 1998-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0222842B1 (en) | Cloning and expression of host-protective immunogens of ibdv | |
EP0324647B1 (en) | Vector for the expression of fusion proteins and protein immunogens | |
Azad et al. | Expression in Escherichia coli of cDNA fragments encoding the gene for the host-protective antigen of infectious bursal disease virus | |
JPS61274687A (en) | Tissue surface antigen of pig mycoplasma and vaccine and diagnostic method based thereon | |
EP0151079A2 (en) | Vaccine against epstein-barr virus | |
IE913948A1 (en) | Recombinant feline coronavirus s proteins | |
EP0337589B1 (en) | Recombinant and native group b eimeria tenella immunogens useful as coccidiosis vaccines | |
Dietzschold et al. | Serological characterization of the three major proteins of vesicular stomatitis virus | |
US5578448A (en) | Nucleic acids encoding wild-type measles virus consensus hemagglutinin and fusion polypeptides and methods of detection | |
EP0324648B1 (en) | Recombinant eimeria tenella vaccines | |
AU587624B2 (en) | Expression of host-protective immunogens of ibdv. | |
JP2000139483A (en) | Recombinant vaccine for coccidiosis | |
US5614409A (en) | Production of IBDV VP2 in highly immunogenic form | |
KR0179993B1 (en) | Hog cholera virus vaccine and diagnostic | |
AU643216B2 (en) | Production of IBDV VP2 in highly immunogenic form | |
EP0479866B2 (en) | Pestivirus nucleotide sequences and polypeptides, in particular from hog cholera virus | |
EP0366684B1 (en) | Ibdv vp2 epitope recognised by virus neutralising and protective monoclonal antibodies | |
JP2796287B2 (en) | Cloning and expression of a host-protective immunogen of IBDV | |
US20040063093A1 (en) | Recombinant feline coronavirus S proteins | |
Hu et al. | Studies of TGEV spike protein GP195 expressed in E. coli and by a TGE-vaccinia virus recombinant | |
IE914551A1 (en) | Protective plasmodium falciparum hybrid proteins which contain partial sequences of the malaria antigens HRPII and SERP | |
EP0235754A2 (en) | Composition and methods of use for a lacZ rotavirus fusion protein | |
AU619477B2 (en) | Ibdv vp2 epitope recognised by virus neutralising and protective monoclonal antibodies | |
EP0417524B1 (en) | Antigens and polypeptides derived from babesia (12D3 antigen) | |
WO2006100257A2 (en) | Vaccine and antibodies against parasitic nematodes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): DE FR GB IT NL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1986903153 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1986903153 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1986903153 Country of ref document: EP |